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This thesis was directed at benzodiazepine prescription in general practice with the 
aim of promoting the safe and rational use of benzodiazepines.  The main objective 
was to search for a suitable tool to help general practitioners (GPs) prevent 
potentially harmful long-term use of benzodiazepines by the patients under their care. 
 
Background 
The context of benzodiazepine prescription is the domain of mental health problems. 
In general practice, these problems are among the top reasons for consultation1,2, 
according to the Continuous Morbidity Registration in Nijmegen over the period 1985-
20011,2 (see table 1).  Functional complaints are the most common mental health 
disorders encounter by GPs, followed by depression and anxiety disorders.  
 
Table 1: Impression of the prevalence and incidence of some Mental Health disorders per 
1000 patient years (CMR 1985-2001) in general practice. 
 Incidence Prevalence 
Man Women Man Women 
Functional complaints 62.5 98.2 100.6 187.8 
Depression 3.0 6.1 7.7 13.8 
Anxiety disorder 0.6 1.2 1.3 3.0 
Hyperventilation 3.4 5.4 3.8 6.1 
Learn and behaviour disorder 3.7 1.8 7.5 2.7 
Alcohol addiction 1.9 0.9 9.0 3.2 
Drugs addiction 0.4 0.1 1.0 0.6 
Psychosis 0.3 0.5 3.0 4.1 
Mental retardation 0.2 0.1 4.7 4.4 
Dementia 0.9 1.7 2.2 5.4 
Source: Ziekten in de huisartspraktijk. vd Lisdonk, vd Bosch, Lagro-Janssen. 4th edition 
 
The position of benzodiazepines over time 
When benzodiazepines in the 1960s, were introduced onto the market they were 
initially considered to greatly  improve the treatment of sleep and anxiety problems. 
The drugs had been deemed “safe”, due to a much better effect / side-effect ratio 
than the barbiturates available at that time. Nevertheless within a couple of years, 





were increasing suspicions of cognitive decline3-10. Ever since, the use of 
benzodiazepines has been a topic of discussion between medical professionals11,12, 
patients13 and the public14,15. These discussions focus on therapeutic efficacy, 
scientific evidence of dependence and the legitimacy of prescribing9 these drugs.  
Many patients with mental health problems – in particular anxiety, sleep disturbances 
and functional complaints – preferred the continued use of benzodiazepines and 
denied any side-effects, such as dependence and cognitive impairment. Proof of 
adverse effects took time to accumulate, but became more convincing when 
benzodiazepines, especially in long-term users, were related to car accidents16 and 
falls with major consequences, e.g. fractures17-22.   
These observations resulted in warnings to GPs and other health professionals to 
only prescribe benzodiazepines in the short-term, in order to prevent addiction 
problems. Over the past 20 years this has led to the development of 
(multidisciplinary) guidelines23-28 on the treatment of sleep and anxiety problems that 
can be used by GPs, psychiatrists and other mental healthcare workers.  
 
Frequency of benzodiazepine prescription 
Prescription figures from the Dutch Health Care Insurance Board over the past 10 
years give the impression that a large number of benzodiazepine prescriptions have 
been crossing the pharmacist’s counter. In 1998, approximately 11.6 million 
prescriptions were issued29 for benzodiazepines, while during the period 2001-2005, 
numbers varied from 12 to 12.2 million30 per year in a population of about 16.3 million 
people31. Prescriptions for an anxiolytic or a hypnotic were issued to 1.2 million 
persons and 800 thousand persons per year, respectively. In General Practice, 
approximately 75% of the benzodiazepine prescriptions were repeat prescriptions32 
without any direct doctor-patient contact. 
International comparisons show that this situation is not limited to the Netherlands. 
Despite all the concerns about long-term benzodiazepine use, it remains a common 
phenomenon in many Western countries. To give an impression, figures in one of the 
few international representative, household surveys, varied from 0.5% (Sweden) to 







The ultimate goal of this study was to develop a tool (checklist) for GPs to help 
assess the risk that patients might become long-term benzodiazepine users when 
they receive their first benzodiazepine prescription. 
 
This research was nested in the Nijmegen Health Area study II that measured the 
prevalence of psychiatric morbidity in the general practice population34. Thus, an 
opportunity was created to analyse detailed information on mental health problems 
and benzodiazepine users in general practice. 
 
This thesis had the following aims: 
1 To investigate whether prevalence figures were affected by variations in the 
definition of benzodiazepine use and differences in the study period in which 
benzodiazepine use was measured. 
2 To identify patient-related factors of long-term versus short-term use of 
benzodiazepines in general practice. 
3 To determine the appropriateness of benzodiazepine prescription: Do the mental 
health problems diagnosed by GPs justify the prescription of benzodiazepines, also 
taking into account the duration of benzodiazepine prescription? 
4 To study the extent to which a combination of neighbourhood, patient, GP and 
practice characteristics could explain General Practice Variation in long-term 
benzodiazepine prescription. 
5 To explore the feasibility of a ‘risk indicator’ instrument in terms of its 
acceptance by GPs and its effect on the incidence of new long-term benzodiazepine 
prescriptions in the general practice population. 
 
Thesis design 
The thesis starts with a study on how variations in the definition of ‘benzodiazepine 
use’ and different observation periods affected the prevalence rate of benzodiazepine 
use in an open population. Chapter 2 presents the results of this analysis. 
 
In the literature, risk factors for long-term benzodiazepine use have mainly been 
studied by comparing non-users to long-term users. However, this ignores the fact 





of time and that the problem of long-term use may only apply to a minority who 
continue their use. In view of these observations, patient related-factors were 
compared between short-term users and long-term users in chapters 3 and 4. 
Chapter 3 compared their physical and mental health status, while chapter 4 
compared their medical and mental health history (DSM-IV diagnoses) and their 
coping and psychosocial characteristics.  
The two studies aimed to identify patient-related risk indicators of becoming a long-
term benzodiazepine user within the general practice population. 
 
Chapters 5 and 6 addressed GP factors, practice factors and GPs’ decisions 
concerning the prescription of benzodiazepines. 
Chapter 5 analysed the appropriateness of benzodiazepine prescription at 32 general 
practices. 
Chapter 6 analysed whether GP factors and practice factors contributed to 
characteristics of the patient and practice population in generating long-term 
benzodiazepine use.  
 
Based on the findings in chapters 3 and 4 and on a literature search factors were 
identified that were potentially suitable for inclusion in a risk-indicator tool. A panel of 
GP experts judged the factors on their usability during general practice consultations. 
In this way, a checklist with 6 questions was developed. Chapter 7 presents a 
feasibility study at 21 general practices in which the GPs applied the checklist to 
indicate whether there was a risk of long-term use in patients who received their first 
prescription for benzodiazepines.  
Chapter 8 contains the summary and general discussion of the main results and the 
conclusions of this thesis. Recommendations are made for further research and 
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Background: Different prevalences of benzodiazepine (BZ) use are described in the 
literature. The present study assessed the effects of employing various definitions of 
BZ use and various observation periods on the prevalence rate of BZ use in an open 
population aged 18-74 years. 
Method: In a literature review, prevalence studies were systematically compared. In a 
second stage, a descriptive cross-sectional multipractice study was analysed using 
48,046 prescriptions of BZ in the past year given to a population of 80,315 patients at 
31 general practices in the Nijmegen Health Area. From this database, prevalence 
rates were calculated applying different definitions of BZ use and different 
observation periods. 
Results: In the literature, prevalence rates varied between 2.2 and 17.6%. There was 
wide variation in definitions of BZ use and observation period. In our prescription 
database, depending on the definitions of BZ use and observation period, prevalence 
rates ranged from 0.2% to 8.9%. The ratio of female:male (2:1) remained constant 
irrespective of the prevalence rate. Age distribution varied according to the duration 
of use: among long-term BZ users, approximately 80% were older than 45 years; 
among short-term BZ users, approximately 55% were older than 45 years.    
Conclusions: The wide variation in prevalence rates of BZ use reported in the 
literature can largely be explained by differences in definitions of BZ use and 
observation period. This affected the distribution of some BZ-use-related variables 
such as age. For reliable comparisons of BZ use, standardisation of the definition of 
BZ use is required. A proposal for standardizing methodology is presented.  
Keywords: benzodiazepine, prevalence, short-term benzodiazepine use, long-term 
benzodiazepine use, General Practice, epidemiology. 




Negative health effects (cognitive deterioration, dependence, falls and fractures) 
accompany long-term benzodiazepine use, but beneficial effects of long-term use 
have not been established1-14. Medical authorities in many countries, therefore, 
advise limiting benzodiazepine (BZ) prescription to a small number of time-restricted 
indications (acute insomnia, acute anxiety and alcohol detoxification)15-17. 
Nevertheless, actual medical practice continues to deviate from these 
recommendations and BZs are one of the most frequently prescribed classes of 
drug18,19. 
As the high prevalence of BZ use is a matter of great concern20, many studies have 
been performed on the prevalence of BZ prescription and its use15,18,21-27. These 
studies reported a wide range of prevalence rates (for a review see28) which does 
little to clarify the situation. 
Various authors analysed populations that differed in terms of sex, age, social class 
and years of the study, which resulted in “real” differences in BZ prevalence. The 
studies also differed in their definitions of BZ use (long-term / short-term /ever), in the 
methods used to collect data (interview18;22;29 or searching prescription records30) and 
in the study period over which they actually measured BZ use. This may have 
resulted in “artificial” differences in BZ prevalence and, therefore, hampers the 
monitoring of trends in BZ use. 
The aim of this study was to investigate artificial differences by focusing on two of 
their main sources: differences in the definition of BZ use and differences in the study 
period in which BZ use was measured, further referred to as “observation period”. A 
literature study was performed to demonstrate that there is wide variation in the 
operationalisation of these two aspects and that this leads to the reporting of different 
prevalence rates. Subsequently, the effects of different definitions of BZ use and 
different observation periods were assessed using population-based BZ prescription 
data. We also investigated the effects of different definitions on sex ratio and age. 
Based on the results of these analyses, recommendations are made about 






Subjects and Methods 
First a systematic literature review was performed on the definition of BZ use and 
study methods; secondly, the effects of employing different definitions of BZ use and 
observation periods were investigated in a primary care population of BZ users. 
Literature review 
The aim of the review was to analyse BZ use in open populations in relation to the 
definition  of use and observation period. We used Medline and Psyclit to search the 
literature from 1966 to 2000 with the following entries:” benzodiazepine(s)” 
accompanied by one or two of the following entries: “prevalence”, “epidemiology”, 
“general practice”, “family medicine”, “population characteristics”, “population survey”. 
Also the reference lists of the reports were searched for complementary publications. 
We included population surveys and studies in primary care / general practice in 
which the frequency of BZ use and observation period as well as the method of 
assessing and reporting prevalence rates were explicitly stated. Studies that were 
ambiguous in this respect (for example “regular” or “occasional” use) were 
excluded31-36. The emphasis was on highlighting the diversity of definitions of BZ use, 
rather than on compiling a complete list of definitions. Definitions of BZ use and 
prevalence rates were noted from these publications.  
Observational study at 31 general practices 
The study was the first step in a computerised intervention programme to reduce 
inappropriate use of psychotropic drugs and to measure prevalences of 
psychopathology in the open population18;37. The setting was 31 general practices in 
the Nijmegen Health Area (NHA). The NHA population comprised non-
institutionalised adults from 18 to 75 years of age (total N=± 326,000, Nijmegen N=± 
113,000). Health care in the Netherlands is primary-care based; general practitioners 
(GP) are the gateway to specialised medical care. Specialist care is obtained through 
referral and the specialists have to report back to the GP. In addition, patients have to 
register with a GP to receive medical care38. General practice records, therefore, 
provide an overview of all medical care that a patient receives. In this way, the 
general practice population is virtually identical to the open population. 
At present in the Netherlands, approximately 80% of general practices have 
computerised patient registration systems and the percentage is rapidly increasing. 
To participate in this study the computerised general practice registration system had 
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to have been in operation for at least one year and the GP had to have been working 
at the practice for at least two years. 
We approached 64 practices that fulfilled these criteria and were evenly spread over 
the region. The objective was to recruit a minimum of 30 general practices in the 
NHA. Thirty-two general practices agreed to participate in the study. The reasons for 
non-participation were: involvement in other research projects during the study period 
(21), refusal to be involved in research (5), on holiday (5), no reason (1). One 
practice encountered major problems with its computer during the study period and 
had to withdraw. Therefore, data were available from 31 general practices. The 
registered patient population was 108,960 persons; this covered a third of the NHA 
population. The study population aged 18 to 75 years comprised 80,315 subjects. 
Compared to the Dutch population, the age group 25-44 years was overrepresented 
and the age group 45-74 years was underrepresented. Sex distribution was the same 
as in the Dutch population. The participating general practices did not differ 
significantly from the non-participants with regard to: practice size, number of GPs 
working at the practice, total length of employment of the GP, dispensing practices, 
sex and year of registration. The only significant difference was the higher number of 
GP training centres among the participating general practices ( 2=5.6, p=. 02). In this 
way a representative sample of general practices was recruited. 
BZ prescription data registered between June / July 1996 and May / June 1997 at the 
participating general practices were made anonymous and converted into a 
prescription-database.  
Under the Dutch health insurance guidelines BZs (no OTC) can only be prescribed 
by a medical practitioner and a single prescription of BZ cannot exceed a maximum 
of 30 days. A total of 48,046 BZ prescriptions were converted into prescription 
records. BZ medication included the ATC-coded groups N05BA, CD, CF and CG. 
Anxiolytics included N05BA and hypnotics included N05CD, CF and CG. Each 
prescription record contained the following information: 1) a unique patient 
identification number, birth date, sex, part of the post code, type of health insurance, 
2) date of prescription, 3) the Anatomical Therapeutic Chemical classification (ATC 
code)39 of the drug, 4) the total amount of drug prescribed, 5) dosage and frequency 
per day.  This information was used to construct a medication prescription database, 





use/non-use for each day of the whole observation year. When daily use was not 
specified, we applied the following standard procedure: the prescription records were 
searched for an earlier prescription, which was more specific. If this was available, 
the dosage and frequency were used. If not then we looked for a pattern in the 
prescriptions that reflected a consumption pattern (e.g. 30 tablets every month is 
consistent with a consumption pattern of 1 tablet a day). If none of this information 
was available we used the advised daily dose of the WHO39 (DDD), with the 
exception of oxazepam for which we took 30 mg/day.  
With the aid of this prescription database, BZ use was calculated using the following 
definitions of use from the literature that could be reproduced in our database: 1) 
(over)all BZ use in a year; 2) short-term use, 2a) BZ use for a maximum of 30 days in 
a year, 2b) BZ use for a maximum of 90 days in a year; 3) long-term use, 3a) a 
minimum of 91 days of BZ use in a year, 3b) a minimum of 180 days of BZ use in a 
year, 3c) a full year of BZ use (as a proxy we took a minimum of 330 days of BZ use). 
We combined all the definitions of BZ use with different observation periods, namely 
a year, 3 months, 1 month or 1 day. This combination resulted in prevalence rates for 
a year, 3 months, 1 month and 1 day. Results were calculated over all 
benzodiazepines as well as over anxiolytics and hypnotics as separate group. 
Anxiolytics and hypnotics were defined according to the ATC-codes. 
With the SAS-package, prevalence rates were calculated from this database while 
applying different definitions of BZ use and different observation periods. 
 
Results 
The definitions of BZ use and the observation periods in the literature are described 
in two tables. Table 1 illustrates the effect of employing different observation periods 
on the definition of overall BZ use. Overall BZ use was usually defined as “at least 
once” or “at least one tablet or prescription”. Column 2 shows the different 
observation periods, which ranged from one year to one day. These combinations 
resulted in prevalence rates that ranged from 17.6%22 to 2.2%40. Table 2 illustrates 
the effect of employing different definitions of long-term BZ use (e.g. longer than 6 
months or 12 months, or counting the repeat prescriptions in a given period).  
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Table 1: Consequences of different definitions of BZ use 
BZ use Observation 
period 
Prevalence %  95 C.I. Range Comments NHA  
prevalence 
BZ use during the 
observation period 
with a minimum of 
one tablet or one 
prescription 
1 year 11.0 (9.9-12.2)18 A H 6.6* 
7.4   (6.1-8.9) 22 – 17.6 (15.9-19.4)22  A C 6.6* 
12.1 (11.6-12.7)47;55-10.0 (9.5-10.5)47;55 F 8.9 
6.2  (5.9-6.5)56  I 8.9 
6 months 3.8 (3.7-3.9 )30 K - 
3 months 6.9  (6.7-7.1)54 B 5.2 
1 week 8.6  (7.6-9.7)27 B - 
3 days 14.0 (12.5-15.7)32 J - 
1 day 3.0  (2.7-3.4)26  2.5 
2.2  (1.8-2.6)40 E 2.5 
 
 
Table 2: Consequences of different definitions of long-term or chronic BZ-use  
Definition long-term BZ use Observation 
period 
Prevalence %  95 C.I. Range Comments 
Twelve months (or more)  
 
1 year 1.7 (1.2-2.2)18 A: H 
1.7 (1.1-2.5)22 –5.8 (4.8-6.9) 22 A ,C 
3 months 1.6 (1.3-2.0)24 B, D 
1.6 (1.2-2.1)42 B 
6 weeks 3.5 (3.4-3.7)28;46 B 
3 days 4.7 (3.8-5.8)32 J 
1 day 0.5 (0.4-.6)48 B 
0.9 (0.7-1.3)hypnotics40-0.4 (0.3-0.7)anxiolytics40 E 
More than six months in a year 1 year 3.8 (3.5-4.1)47;55 
3.1 (2.8-3.4)47;55 
F 
1 week 4.9 (4.2-5.8)27 B 
More than 60 days in 6 months 6 months 1.0 (1.0-1.1)30 K 
Prescrip-
tions 
Prescriptions for  
1 year 
1 year 2.2 (1.8-2.7)43 B G 
 3 prescriptions 3 months 2.6 (2.4-2.9)44 B G 
 
Index for tables 1 and 2 
A = only anxiolytics  
B = rates derived from General Practice computerised prescription data 
C= multinational study, only lowest and highest rates are listed 





E= Survey, telephone interview 
F= pharmacy records from population of 1 village in 1983 and 1992 
G= repeat prescriptions 
H= anxiolytics comprising 84% BZ+ 16% barbiturates 
I = pharmacy records adjusted for national estimates 
J = patients who visited the general practice in the observation period 
K= pharmacy record health maintenance organisation 
* only anxiolytics 
 
 
Many different observation periods were applied to one BZ use definition (column 2). 
The prevalence rates did not show any systematic relation with the various BZ use 
definitions or the different observation periods.  
In the second part of the study we investigated the effects of employing different 
definitions of BZ use and different observation periods in our prescription database 
(table 3). In one year, nearly nine per cent (8.9%) of the patients received at least 
one prescription of BZ. The percentage of long-term users varied with the definition. 
With the most restrictive duration of one year of use, 0.6% were classified as "long-
term user"; with more than 180 days of use 2.0% were classified as “long-term users” 
and with more than 90 days of use 2.9% were classified as “long-term users”. 
Likewise, the percentage of short-term users was lowest when the more restrictive 
definition of BZ use was employed (3.4% with  30 days) and highest when the less 
restrictive definition was employed (4.0% with  90 days). 
The observation period also affected the prevalence of BZ use: the longer the 
observation period, the higher the prevalence. With a observation period of 1 day, 
2.5% were classified as (all types of) BZ user; with 1 month 3.7% were users; with 3 
months 5.2% were users and with 1 year 8.9% were users. The effect of varying the 
observation period interacted with the type of BZ use (short-term or long-term) and 
proved to be more powerful for short-term than for long-term BZ use. For long-term 
use (defined as a full year of BZ use) the different observation periods had virtually 
no effect. For short-term use, the prevalence rate for  30 days varied from 0.2% with 
a 1-day observation period to 3.4% with a 1-year observation period. 
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Table 3: Effects of varying the definitions of BZ use and observation period on 
prevalence rates of benzodiazepine use 
 









1-365 days 8.9%* 5.2% 3.7% 2.5% 
Short-term use definitions 
 30 days 3.4%** 1.4% 0.6% 0.2% 
 90 days 4.0%** 1.9% 0.9% 0.4% 
Long-term use  definitions  
> 90 days 2.9% 2.8% 2.5% 2.0% 
 180 days 2.0% 2.0% 2.0% 1.7% 
1 year 0.6% 0.6% 0.6% 0.6% 
* Prevalence corrected for the age-sex distribution of the Dutch population: 9.5% 
** Missing data due to overlap observation period 
 
Different definitions of BZ use and different observation periods also affected the 
prevalence rates of anxiolytics and hypnotics. When, for example we varied the 
definition of BZs but employed a fixed observation period (of 1 year), table 3 column 
1 showed that the prevalence rate for that BZ use definition was 8.9%; for BZ use of 
 90 days, it was 4.0%; for BZ use of  180 days, it was 2.0%; and for the remaining 
definition, it was 2.9%. For anxiolytics only, these percentages were 5.3%, 1.0%, 
2.6% and 1.7% respectively. For hypnotics only, these percentages were 2.3%, 
0.5%, 1.2% and 0.7% respectively. Missing values were caused by users of 
anxiolytics and hypnotics combined. Note that the rate of anxiolytics by hypnotics for 
this year prevalence was about 2:1. 
We investigated what the consequences were on the sex/age characteristics of BZ 
users. In each of the calculated BZ use prevalences, 61.3%- 65.5% were female; 
among the non-users, 49.5% were female (Dutch population 49.9%). Irrespective of 
how the prevalence was generated, the ratio of female users to male users remained 
fairly constant 2:1 (see table 4). Table 5 illustrates that employing different definitions 
and observation periods caused the distribution of age to fluctuate. In the short-term 





(1 year/year), 81.7% were 45+ (Dutch population 42.1%). The proportion of 45+ was 
fairly constant in the long-term users. In the short-term users, the longer the 
observation period, the lower the proportion of over 45-year-olds (  90 days/day 
62.2% were 45+;  90 days/year 53.8% were 45+). 
 
Table 4: Proportion (%) of female cases in the prevalence rates of BZ use 
 








All use % female 
1-365 days 63.9 65.5 65.4 65.2 
Short-term use definitions % female 
 30 days 61.3 62.0 61.6 62.7 
 90 days 62.3 64.1 64.1 64.3 
Long-term use  definitions  % female 
> 90 days 
65.2 65.3 65.0 65.1 
 180 days 64.3 64.3 64.2 64.0 




Table 5: Proportion  (%) of people aged > 45 years in prevalence rates of BZ use 
 








All use definitions % > 45 years 
1-365 days 62.6 69.7 73.7 76.1 
Short-term use definitions % > 45 year 
 30 days 51.1 51.5 51.3 55.9 
 90 days 53.8 56.4 57.9 62.2 
Long-term use  definitions  % > 45 years 
> 90 days 79.0 79.4 79.6 78.7 
 180 days 80.7 80.7 80.6 80.2 
1 year 81.7 81.7 81.7 81.6 
 




This study focused on two methodology-related issues that affected BZ prevalence 
rates, namely the definition of BZ use and observation period. In the literature, two 
major sources of variation in BZ use are mentioned, real (e.g. country) and artificial 
(e.g. definition of BZ use). We did not find any systematic pattern in prevalence rates 
in relation to the definition of BZ use or the observation period. This lack of a pattern 
might be the result of other differences between studies, such as the inclusion or 
exclusion of drugs labelled as “BZ”, method of data collection, country, study year 
and population composition41. 
We compiled a prescription database, comparable with those described in the 
literature, to investigate the effect of varying the definition of BZ use and the 
observation period. The longer the observation period, the higher the prevalence, 
owing to the inclusion of short-term users. “Long-term” users, on the other hand, 
were always included irrespective of the length of the observation period. Varying the 
observation period had little effect on the male:female ratio, but resulted in 
substantial differences in age distribution. The longer the observation period, the 
lower the proportion of older BZ users, because of the inclusion of more short-term 
BZ users. Our results on long-term BZ users were comparable with those reported in 
the literature with respect to their being older (45+ years). Broadly speaking, our 
results regarding BZ use also applied to anxiolytics and hypnotics. 
 
Methodology-related aspects 
Part of this study comprised an analysis of prescription records from general practice. 
In the literature registered prescription data are a widely accepted source of 
data24;27;28;42-49. For example, Wright described a point prevalence of 0.5% for long-
term daytime BZ use (> 1 year) in the UK, while we found 0.6% for day and night-
time BZ use several years later28.  Patients who received a prescription for BZs were 
regarded to be BZ users, but it is impossible to say whether the prescription resulted 
in actual BZ use. Therefore, BZ use may have been over estimated. Although 
prescription does not necessarily imply use, it can be expected that the effects of 
different definitions on prescription rates also apply to user rates. A flaw in our design 
of short-term BZ use was that we had not foreseen the problem that prescription 





obtain the BZ use characteristics for all patients for a full year, it would be better to 
extend the observation period slightly, for example to 14 months, to make it easier to 
classify the BZ users who overlap the beginning or end of the observation period. 
Some studies count prescriptions, but this method is less accurate than the method 
we applied, because medication can be prescribed for a few days to one month (e.g. 
psychofarmaca) or even several months (e.g. other medication). Some other studies 
used interviews as a method of data collection18;22;23;26;29;40;50, which may have 
produced more reliable information about actual BZ use. A disadvantage of 
interviews is bias caused by (selective) recall or by leading questions, or random bias 
caused by the response set. Janson remarked "the evidence is overwhelming that 
recollecting tends to decrease with the time span involved"51-53. The method of data 
collection is one of the sources of artificial differences in prevalence; other sources 
are the research design (cross-sectional or longitudinal) and the research sample 
(age range, age composition and sex composition). 
Although the variation in reported BZ use is the consequence of a number of factors, 
our framework of varying BZ use definitions and observation periods resulted in fairly 
consistent results. Compared to other studies in the Netherlands, for instance Van 
Hulten’s47 long-term BZ use (more than six months BZ use in a 1-year observation 
period) was 3.1% in 1992, while ours was 2.0% in 1997. The overall prevalence in 
Van Hulten’s study was 10.0%, while after being corrected for the age-sex 
distribution of the Dutch population, ours was 9.5%. Our results were also consistent 
with the overall prevalence in the study by Van de Waals54 reported in 1987. A 3-
month observation period led to a prevalence of 6.9% compared to our prevalence of 
5.2%. Controlling for methodology variation would make it possible to uncover 
relevant differences in BZ use between countries and cultures22 and this could 
provide a starting point for more in-depth analysis of the reasons behind the gap 
between desired and observed BZ use. 
Uniformity of criteria and observation periods is vital. This study emphasizes the need 
to standardize the criteria for investigating BZ use, in order to be able to make 
meaningful comparisons. On the basis of our Dutch population, we developed a 
framework for converting reported prevalence rates by taking into account differences 
in two important variables that cause artificial differences. It may be possible to 
develop a universal conversion method that is suitable for making comparisons 
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between various studies. However, from our experience this seems to be a 
cumbersome approach. An alternative would be to reach international consensus 
about study procedures. Firstly, we propose employing an observation period of 1 
year, because this is the standard measure of prevalence. Secondly, there should be 
only 3 (reference) definitions of BZ use (anxiolytics and hypnotics together): (1) any 
use in the past year (ever), (2) short-term use in the past year with a maximum of 3 
months (the advice of the WHO) and (3) long-term BZ use in the past year when 6 
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Background: Despite generally accepted advice to keep treatment short, 
benzodiazepines are often prescribed for more than six months. Prevention of long-
term benzodiazepine use could be facilitated by the utilisation of risk indicators for 
long-term use. However, the characteristics of long-term benzodiazepine users 
described in the literature are based on studies in which long-term users were 
compared with non-users. Thus these characteristics may be imprecise.  
Aim: To study the characteristics of long-term benzodiazepine users by comparing 
their demographic data and health status (mental and physical) with those of short-
term users.  
Design of study: Cross-sectional comparison of short-term and long-term 
benzodiazepine users.  
Setting: Patients from 32 GP practices of the Nijmegen Health Area, The 
Netherlands.  
Method: The characteristics of 164 short-term and 158 long-term benzodiazepine 
users in general practice were compared, using interview data and morbidity, referral 
and prescription data from GP records.  
Results: Long-term benzodiazepine users were (a) older, (b) had a more severe 
history of mental health problems for which they had received more serious 
treatment, (c) used more psychotropic drugs, (d) had a higher hospital specialist 
consultation frequency, (e) had more diagnoses of the following: diabetes, asthma, 
chronic obstructive pulmonary disease, hypertension, a serious skin disorder, and (f) 
reported a lower perceived general health status. There were no sex differences.  
Conclusion: Specific risk characteristics of long-term benzodiazepine users can be 
used to develop a risk profile for the management of benzodiazepines in general 
practice. We believe that (somatic) secondary care also contributes to 
benzodiazepine use. It may be worthwhile to coordinate care for benzodiazepine 
users between GPs and hospital specialists. 
Keywords: benzodiazepines; prescriptions failure; health status 




Long-term benzodiazepine use is a precarious theme in general practice. The 
guidelines
1-3 
recommend short intervention (maximum of 8 to 12 weeks),  never-
theless 1.7% to 4.9% of the population receive benzodiazepine prescriptions for 
more than six months.
4-12 
Apparently, despite the fact that the initial benzodiazepine 
prescription is the result of carefully weighing benefits against risks, some patients 
end up as long-term users.  
Specific patient characteristics could be responsible for long-term use, and this is 
supported by the literature. Based on the comparison of long-term users with non-
users, the following health status factors were related with long-term benzodiazepine 
use: older age, psychological problems (more), physical disease (more), and sex 
(female).
8,11,13-21 
It is unclear however, if this refers specifically to long-term 
benzodiazepine users or to benzodiazepine use in general. Only a few studies have 
compared long-term with short-term benzodiazepine users: they were older, had 
poorer health, more depression, a higher daily benzodiazepine use and got their 
prescription more often from a hospital physician.22,23  
An alternative explanation for long-term use that is patientunrelated would be 
prescription failures. A minimal failure to discontinue initial benzodiazepine use (for 
example, in 1% of prescriptions) would cumulate in a prevalence of long-term use of 
1 per 1000 patients per year (under a prescription rate of 10%
12,24
). Prescription 
failure is plausible, given that most repeat prescriptions are provided without a 
doctor–patient encounter
25,22 
As a consequence a proportion of the original short-
term benzodiazepine users become long-term users. Further insight into 
benzodiazepine use is needed to develop a tool for prevention of long-term use. 
Therefore, this study compared the physical and mental health status of long-term 





The design of this study was a cross-sectional comparison of short-term and long-
term benzodiazepine users in general practice. Data were used from the practices of 







Benzodiazepine users were identified from the practices’ prescription 
files.  
 
Definition criteria for benzodiazepine users  
Under the Dutch health insurance guidelines, benzodiazepines (defined according to 
the standardised classification system for drugs of the WHO using the Anatomical 
Therapeutic Chemical classification — index groups N05BA, CD, CF and CG;
27 
N = 
nervous system, N05 = psycholeptics, N05B = anxiolytics, N05C = hypnotics and 
sedatives, N06 = psychoanaleptics) have to be prescribed by a medical practitioner. 
Short-term benzodiazepine users were defined as having prescriptions for less than 
or equal to 90 days (the maximum prescription advice of the WHO) with the exclusion 
of patients who finished taking the drug at the beginning of the measurement period 
or who started at the end of that period, because of uncertainty about their user 
pattern. Long-term benzodiazepine users were defined as having prescriptions for 




Practices and patients  
General practitioners (GPs) had to be using a computerised patient and medication 
registration system. In total, 64 practices were approached and 32 agreed to 
participate. Practices’ main reason for non-participation was involvement in other 
research; details of approach and representativeness of the general practices and 
the population samples have been described elsewhere.
24,26 
The general practice 
patients’ lists comprised 80 315 persons aged between 18 and 74 years, of whom 
4% were short-term and 2% long-term benzodiazepine users.
24 
An equal number of 
short-term and long-term benzodiazepine users were recruited from each practice to 
eliminate effects related to a GP’s work style. This resulted in the selection of 164 
short-term users and 158 long-term benzodiazepine users for the study. There were 
no sex differences between the groups selected for this study or between all the short 
and long-term benzodiazepine users at the practices. With respect to age, the short-
term benzodiazepine user participants were older than all the short-term users at the 
practices (participants aged over 45 years = 63.4%, versus practices = 53.8%).
24  





Health status was measured using:  
1 the 24-item chronic diseases list of the CBS in the past year based on the 
Health Survey of Statistics Netherlands,
28 
the Short Form 36-item Health Survey (SF-
36),
29,30 








2 a structured interview concerning the patient’s history of mental health 
problems and details about treatment, hospitalisation for psychiatric diseases, drug 
and alcohol abuse and treatment. Patients were also asked about their use of over-
the-counter (OTC) psychotropic drugs in the past four weeks and the frequency with 
which they had consulted a hospital specialist (excluding visits to an ophthal-
mologist). The GP records provided data on the number of consultations and the 
psychotropics prescribed during the past year. The psychotropics were defined using 
Anatomical Therapeutic Chemical classification codes
27
: N05 and N06, (N06 = 
psychoanaleptics) with the exception of the benzodiazepines named earlier.  
 
Analyses  
The recruited sample was split in two parts so that the risk profile found in the first 
part (split 1) could be validated in the second part (split 2).
34 
To detect differences of 
at least 16% between long-term and short-term benzodiazepine users, two groups of 
95 subjects were necessary (if α = 0.05 and β = 0.20) or the first split. All subjects 
were stratified for each practice. Subsequently univariate procedures (ϰ
2
-test, t-test) 
on single variables were used to select significant variables for the logistic 
regression, resulting in a risk profile. The goodness-of-fit method was used,
34 
testing 
observations from the second split (subsample of 69 short-term and 63 long-term 
benzodiazepine users) with the findings of the first split. Analyses were done with the 







The long-term users were older (mean age = 56.8 years versus 48.5 years), but there 
was no sex difference between the two groups. Many long-term and short-term users 
had a history of mental health problems (48% and 42%, respectively). However, 
more long-term benzodiazepine users had been treated by a psychiatrist and had a 
history of alcohol abuse. As a large proportion of the patients with alcohol problems 
also had psychiatric problems, we regarded these two aspects as a history of 
treatment in secondary health care — 35.8% long-term users, 14.7% short-term 
users. In contrast, more short-term benzodiazepine users had been treated for 
psychological problems in primary care — 27.4% versus 12.6%.  
Long-term benzodiazepine users had received more antidepressants and 
antipsychotics (32.6% versus 13.7%) in the past year and visited a hospital specialist 
more often (mean number of visits = 2.4 versus 1.3). Both groups reported one or 
more chronic disease in more than 80% of cases, but among long-term 
benzodiazepine users there was significantly more diabetes, asthma or chronic 
obstructive pulmonary disease (COPD), hypertension or a serious skin disorder 
(combined in 50.5% versus 24.2% of short-term users). Therefore ‘chronic diseases’ 
were taken as one category in the logistic regression risk profile.  
Long-term benzodiazepine users had poorer perceived general health (mean GHQ 
score = 56.8 versus 65.9), physical functioning (mean SF-36 score = 78.3 versus 
85.8) and mental health (mean 4-NS score = 64.3 versus 71.4). Otherwise, the 
scores on SF-36 GHQ30 and 4-NS were elevated in both groups. Also, reported OTC 
psychotropic use and the GP consultation frequency were similar.  
All the above-named significant variables of the first split were entered into the 
logistic regression. Controlling for redundancy in logistic regression eliminated 
perceived general health and physical functioning. We controlled for confounding of 
age, but all the variables were independent. Because the outcome of the second split 
logistic regression was comparable with that of the first (AUC1 = 0.77 ± 0.7; AUC2 = 
0.80 ± 0.8) Table 1 gives the logistic regressions of both splits combined — older 
age, a history of psychiatric treatment, and chronic illness were independently related 
to long-term benzodiazepine use.  
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Table 1: Logistic regression of the health status factors of long-term benzodiazepine users 
compared with short-term users (first split and second split combined, missing n=3) 





Intercept - - < 0.001 
Age > 50 year 3.18 1.84-5.50 < 0.001 
> 1 Consult frequency specialist past half year 1.56 0.93-2.59 0.09 
History of  treatment in secondary care (psychiatrist) and/or 
treatment for alcohol abuse 
2.80 1.49-5.29 0.001 
Diabetes mellitus or asthma or COPD or hypertension or a 
serious skin disorder  
2.33 1.38-3.93 0.001 
Mental Health (SF 36) 1.93 1.15-3.22 0.012 
Prescribed psychotropics (antidepressives and 
antipsychotics) 
2.52 1.32-4.81 0.005 
Concordant         75.9% 
Discordant         21.1% 




The study provided the profile of long-term benzodiazepine users; they were older, 
had a more severe psychiatric history, had frequent prescriptions of psychotropics, 
and poorer mental health status, with more common chronic diseases and more visits 
to medical specialists.  
Not included in the analysis were socioeconomic status, coping behaviour or GPs’ 
work style. In fact the long-term users we studied were long-term users despite the 
efforts of their GP to use benzodiazepines in a more appropriate, short-term or 
intermittent way. As we did not study the GP–patient interaction in benzodiazepine 
use and prescribing we are not able to comment on this in depth.  
Our findings differ from others with respect to sex as well as showing some 
unexpected similarities,
8,11,14-21 
in all probability due to our comparison with short-term 
benzodiazepine users rather than non-users. In particular this was the case for the 
elevated scores on SF-36 and GHQ
30, 
29,31 
indicating that long- and short-term 
benzodiazepine users have many psychiatric symptoms and a broad range of 





chronic diseases was interesting. A possible explanation for this is that these are all 
diseases with highly protocolised
35-38 
treatments that require frequent visits to primary 
and secondary care physicians. As the second split confirmed the findings of the first 
split, we are confident that these characteristics are indeed specific for long-term 
benzodiazepine users.  
Frequent visits to a physician in themselves increase the chance of starting 
prescriptions for drugs like benzodiazepine. Moreover, treatment started in secondary 
care may be continued in primary care. This is in line with the reported role of 
(somatic) hospital specialists
23 
as well as the described role of follow-up prescriptions 
in general practice.
22,25





effects) and their consequences
40 
and given that 
stopping benzodiazepine therapy is a problem for many patients,
41-43 
it is important to 
prevent long-term use.  
Recapitulating, we found specific risk indicators for long-term benzodiazepine use, 
and so patient-unrelated prescription failures are an improbable cause of long-term 
use. Many of the risk indicators we found suggest the involvement of secondary care, 
which can only be dealt with by accurate communication and coordination of the 
various disciplines by the GP. More research will provide greater insight into the role 
of these indicators in creating long-term benzodiazepine users. Further exploration of 
differences between short- and long-term benzodiazepine users is desirable (for 
example, coping). The findings of this study will be used in developing GP support to 




We would like to thank the participating practices and patients for their cooperation during 
this study. 
This work was funded by a grant of the Prevention Fund, now known as the Council for 
Medical and Health Research (ZonMw). 




1. Committee on the Safety of Medicines (CSM). Benzodiazepines, dependence and withdrawal 
symptoms. Curr Probl 1988; 21: 1-2.  
2. Salzman C. The APA Task Force report on benzodiazepine dependence, toxicity, and abuse. 
[Editorial.] Am J Psychiatry 1991; 148: 151-152.  
3. Gabe J. Promoting benzodiazepine withdrawal. Addiction 1994; 89: 1497-1504.  
4. Balter MB, Manheimer DI, Mellinger GD, Uhlenhuth EH. A crossnational comparison of anti-
anxiety/sedative drug use. Curr Med Res Opin 1984; 8 (Suppl 4): 5S-20S.  
5. Barbui C, Gregis M, Zappa M. A cross-sectional audit of benzodiazepine use among general 
practice patients. Acta Psychiatr Scand 1998; 97:153-156.  
6. Magrini N, Vaccheri A, Parma, et al. Use of benzodiazepines in the Italian general population: 
prevalence, pattern of use and risk factors for use. [See comments.] Eur J Clin Pharmacol 
1996; 50:19-25.  
7. Mellinger GD, Balter MB, Uhlenhuth EH. Anti-anxiety agents: duration of use and 
characteristics of users in the USA. Curr Med Res Opin 1984; 8 (Suppl 4): 21S-36S.  
8. Mellinger GD, Balter MB, Uhlenhuth EH. Prevalence and correlates of the long-term regular 
use of anxiolytics. JAMA 1984; 251: 375-379.  
9. Ohayon MM, Caulet M, Priest RG, Guilleminault C. Psychotropic medication consumption 
patterns in the UK general population. J Clin Epidemiol 1998; 51: 273-283.  
10. Rodrigo EK, King MB, Williams P. Health of long-term benzodiazepine users. BMJ 1988; 296: 
603-606.  
11. Salinsky JV, Dore CJ. Characteristics of long-term benzodiazepine users in general practice. J 
R Coll Gen Pract 1987; 37: 202-204.  
12. Van Hulten R, Leufkens H, Bakker A. Usage patterns of benzodiazepines in a Dutch 
community: a 10-year follow-up. Pharm World Sci 1998; 20: 78-82.  
13. Wells K, Kamberg C, Brook R, et al. Health status, sociodemographic factors, and the use 
of prescribed psychotropic drugs. Med Care 1985; 23: 1295-1306.  
14. Ashton H, Golding JF. Tranquillisers: prevalence, predictors and possible consequences. Data 
from a large United Kingdom survey. Br J Addict 1989; 84: 541-546.  
15. Blijenberg-Ruis B, Garretsen HFL, Schuurman JH, Verdonk ALT. The use of sleep medication 
and tranquilizers. Tijdschrift voor Sociale Gezondheidszorg 1986; 64: 491-497.  
16. Catalan J, Gath DH, Bond A, et al. General practice patients on long-term psychotropic drugs. 
A controlled investigation. Br J Psychiatr 1988; 152: 399-405.  
17. Gene BJ, Blay PC, Soler VM. Risk factors in the use of benzodiazepines. Fam Pract 1988; 5: 
283-288.  
18. Lagro-Janssen ALM, Liberton ILW. Profiles of regular consumers of benzodiazepines in a 





19. Mellinger GD, Balter MB, Manheimer DI, et al. Psychic distress, life crisis, and use of 
psychotherapeutic medications: national household survey data. Arch Gen Psychiatr 1978; 35: 
1045-1052.  
20. Simpson RJ, Power KG, Wallace LA, et al. Controlled comparison of the characteristics of 
long-term benzodiazepine users in general practice. [See comments.] Br J Gen Pract 1990; 
40: 22-26.  
21. Uhlenhuth EH, Balter MB, Lipman RS. Minor tranquilizers: clinical correlates of use in an 
urban population. Arch Gen Psychiatr 1978; 35: 650-655.  
22. Vissers FHJA, Jongbloet AH, Knottnerus JA. Benzodiazepinen: de gebruiker en zijn huisarts. 
[Benzodiazepines, the user and his general practitioner.] Huisarts en Wetenschap 1998; 41: 
323-327.  
23. Isacson D. Long-term benzodiazepine use: factors of importance and the development of 
individual use patterns over time — a 13year follow-up in a Swedish community. Soc Sci Med 
1997; 44: 1871-1880.  
24. Zandstra SM, Furer JW, Lisdonk van de EH, et al. Different study criteria affect the prevalence 
of benzodiazepine use. Soc Psychiatr Psychiatr Epidemiol 2002; 37: 139-144.  
25. Van der Waals, FW. Sex differences among recipients of benzodiazepines in Dutch General 
Practice. Amsterdam: Academic Medical Centre, University of Amsterdam, Department of 
Women’s Health. Thesis. 1995.  
26. König-Zahn C, Furer JW, Tax B, et al. Regioproject Nijmegen 2: Psychiatrische morbiditeit in 
de regio.[The Nijmegen Health Area Project No 2: psychiatric morbidity in NHA2.] Nijmegen: 
UMC Nijmegen, Department of Social Medicine, General Practice and Psychiatry, 1999.  
27. WHO Collaborating Centre for Drugs. Statistics Methodology Guidelines ATC Classification 
and DDD Assignment. Oslo: WHO/NCM, 1996.  
28. van den Berg J, van den Bos GAM. Het (meten van het) voorkomen van chronische 
aandoeningen 1974-1987. [The (measurement of the) presence of chronic disorders.) 
Maandblad Gezondheid (CBS) 1989; 4-21.  
29. Ware JE, Snow KK, Kosinski M., Gandeli B. SF-36 Health Survey. Manual and interpretation 
guide. Boston: The Health Institute, New England Medical Center, 1993.  
30. Van der Zee K, Sanderman R. Het meten van de algemene gezondheidstoestand met de 
RAND-36: een handleiding. RU Groningen: Noordelijk Centrum voor Gezondheids-
vraagstukken, 1993.  
31. Goldberg DP, Williams P. A user’s guide to the General Health Questionnaire. Windsor: 
NFER-Nelson, 1988.  
32. Koeter MWJ, Ormel J. General Health Questionnaire Nederlandse Bewerking (Manual). Lisse: 
Swets and Zeitlinger, 1991.  
33. Jorm AF, Duncan-Jones P. Neurotic symptoms and subjective well-being in a community 
sample: different sides of the same coin? Psychol.Med. 1990; 20: 647-654.  
34. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley Interscience, 1989; 
171-175.  
Differences in health status between long-term and short-term benzodiazepine users 
 
43 
35. Geijer RMM, Thiadens HA, Smeele IJM, et al. NHG-standaard COPD en astma bij 
volwassenen: diagnostiek. [Guidelines of the Dutch College of General Practitioners on 
asthma in adults — diagnosis.] Huisarts en Wetenschap 2001; 44: 107-117.  
36. Geijer RMM, Van Schayck CP, Van Weel C, et al. NHG-standaard COPD: behandeling. 
[Guidelines of the Dutch College of General Practitioners on COPD.] Huisarts en 
Wetenschap 2001; 44: 207-219.  
37. Rutten GEHM, Verhoeven S, Heine RJ, et al. NHG-standaard diabetes mellitus type 2. 
Huisarts en Wetenschap 1999; 42: 67-84.  
38. Walma EP, Grundmeijer HGLM, Thomas S, et al.(eds). NHG-Standaarden voor de huisarts I. 
Maarssen: Elsevier/Bunge, 1999: 187-205.  
39. Tata PR, Rollings J, Collins M, et al. Lack of cognitive recovery following withdrawal from long-
term benzodiazepine use. Psychol Med 1994; 24: 203-213.  
40. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to 
femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155: 
1801-1807.  
41. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of 
benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatr 1990; 47: 899-907.  
42. Power KG, Jerrom DW, Simpson RJ, Mitchell M. Controlled study of withdrawal symptoms 
and rebound anxiety after six-week course of diazepam for generalised anxiety. BMJ 1985; 
290: 1246-1248.  
43. Lader MH. Limitations on the use of benzodiazepines in anxiety and insomnia: are they 











Long-term benzodiazepine users in family practice: 
differences from short-term users in mental health, 





E. van Rijswijk 
C.A.Th. Rijnders 
E.H. van de Lisdonk 
J.H.J. Bor 











Background. Contrary to short-term use, long-term benzodiazepine use is 
undesirable. Nevertheless, its prevalence is high. To prevent long-term use, it is 
important to know which short-term users are at risk of becoming long-term users. 
Objectives. The purpose of the present study was to identify patient-related factors of 
long-term versus short-term use of benzodiazepines. 
Methods. A cross-sectional study was carried out in family practices among users of 
benzodiazepines with regard to DSM-IV diagnosis, coping and psychosocial 
characteristics. In a multivariate logistic regression analysis, long-term use of 
benzodiazepines was the dependent variable. 
Results. A total of 164 short-term and 158 long-term benzodiazepine users 
participated in the study. Having a DSM-IV disorder and psychiatric co-morbidity, 
being older, less educated, lonely and using more avoidance coping behaviour was 
associated with long-term use of benzodiazepines compared with short-term use. 
Conclusion. The associations found point to possibilities to reduce long-term 
benzodiazepine use, for example if patients with these characteristics are treated 
with the alternatives to benzodiazepines or are monitored closely for a short period 
after being prescribing benzodiazepines. 
Keywords. benzodiazepine, coping, DSM-IV diagnosis, family practice, psychosocial 
circumstances. 
 




Guidelines advise benzodiazepines for short periods of time, on strict indications, but 
discourage their longer use because of side effects (dependency, cognitive 
impairments, falls and traffic accidents).1 Yet daily practice, with long-term use by 1–
8% of the population, is quite different.2 The reasons for the discrepancy are not 
clear, but are probably related to sub-DSM-IV mental health problems and 
psychological distress that is not classified as formal ‘psychiatric’ morbidity. This is at 
the core of the dispute on the long-term efficacy of benzodiazepines.  
As not all those prescribed benzodiazepine will become long-term users, it is 
worthwhile to investigate which factors are associated with long-term use. For 
instance, comparing psychiatric morbidity, psychosocial circumstances and coping in 
short- and long-term users might identify such risk factors. A literature search in 
Medline, Psyclit and Pubmed on psychiatric diagnosis (DSM-IV or ICD-10) of long-
term benzodiazepine users in family practices yielded only a few publications. 
Ohayon described DSM-IV mental disorders, yet did not specify the duration of 
benzodiazepine use.3 Vissers concluded in a comparison of long- versus short-term 
users that coping with life’s problems, but not the experienced life problems 
themselves, were a determinant,4 but did not analyse psychiatric morbidity. Most 
studies compare long-term users with non-users,5,6 which is less relevant for the 
prediction of long-term use.  
The aim of our study is to identify patient-related factors of long-term benzodiazepine 
use in family practice.  
 
Material and methods 
This cross-sectional study compared short- and long-term benzodiazepine users in 
family practices with regards to DSM-IV diagnosis, coping and psychosocial 
characteristics. A survey on psychopathology in the practice population of 32 family 
practices provided the study data.2 In the Dutch health care system, every citizen is 
registered with a family physician, and practice populations are therefore equivalent 
to the general population. Participating family physicians had to have a computerized 
patient and medication registration system, which currently is the case for >80% of 
practices. The 64 practices in the region fulfilling these criteria were approached, of 





population have been described.2 Participating practices comprised more training 
practices (chi-square = 5.6; P = 0.02) and had fewer patients aged 45–74 but more 
aged 25–44 in their practice list compared with the Dutch average. The practice 
populations contained 4% short-term and 2% long-term benzodiazepine users, which 
is similar to other Dutch studies.7,8 To control for family physicians’ work style, equal 
numbers of short and long-term users were selected randomly from every practice. 
Benzodiazepines were defined as the ATC-coded groups N05BA, CD, CF and CG. 
Benzodiazepine use was defined as one or more prescriptions recorded in the 
computerized family practice prescription files. For every registered patient, the 
prescription was translated into use/non-use for each day, using the issued daily 
dosage and number of tablets, for the previous 12 months.  
Use was defined according to WHO criteria9,10 as short-term (prescribed 
benzodiazepine for ≤90 days) and long-term (prescribed for ≥180 days). Those 
patients who used benzodiazepines for 91–179 days were excluded.  
The psychosocial characteristics of every patient were determined using the following 
(i) Social Support List for Interactions, 12-item version (SSL 12-I)11; (ii) Loneliness 
questionnaire12; (iii) Brugha questionnaire13; (iv) socioeconomic status (SES), income 
and education level; and (v) three questions from the Ontario Health Survey14 on 
traumatic youth experiences: “were you placed in a children’s home?”; “were you 
placed in a youth detention centre?”; and “were you raised in foster homes before the 
age of 16?”   
The short version ‘Coping Inventory for Stressful Situations’ (CISS)15 was 
administerd to determine how the patients were coping and any psychiatric disorders 
were determined by the Schedules for Clinical Assessment in Neuropsychiatry 
version 2.1 (SCAN-2.1).16 A clinical psychologist, purpose-trained for this study, 
conducted all the interviews.  
For all SCAN data, DSM-IV diagnoses were automatically computed by means of the 
SCAN-2.1 algorithm (Table 1).16  
First, univariate analyses of the caseness (presence of at least one specific 
diagnosis), as well as the total scores of the questionnaires were carried out with 
long-term benzodiazepine use as dependent variable. Secondly, all independent 
variables were introduced into a multivariate logistic regression analysis, followed by 
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a manual backward procedure. All analyses were performed with the SAS statistical 
software package.  
 
Table 1. Univariate results of psychosocial circumstances and DSM-IV diagnosis for short-










or Fisher’sc exact 
test 
DSM-IV Caseness   0,010*b 
 No case 82 (67.2%) 66 (51.6%) 
  Case: one diagnostic category 30 (24.6%) 37 (28.9%) 
 Case: 2-8 diagnostic categories 10 (8.2%) 25 (19.5%) 
DSM-IV Diagnostic Category  
Psycho-organic disorder 0 (0%) 1 (0.8%) 1.0c 
Substance related disorder 6 (4.9%) 14 (10.9%) 0.103c 
Psychotic disorder 1 (0.8%) 2 (1.6%) 1.0c 
Mood disorder 13 (10.7%) 23 (18.0%) 0.108c 
Anxiety disorder 13 (10.7%) 24 (18.8) 0.077c 
Eating disorder 1 (0.8%) 1 (0.8%) 0.273c 
Somatoform disorder 7 (5.7%) 10 (7.8%) 0.618c 
Sleeping disorder 13 (10.7%) 22 (16.4%) 0.149c 
Dissociative disorder 2 (1.6%) 6 (4.7%) 0.282c 
Other DSM-IV disorder 0 (0%) 2 (1.6%) 1.0c 
Gender 
Female 79 (64.8%) 88 (68.8%) 0.6b 
Age 48.1 57.4 0.0000*a 
SES / Netto Income/ month   0.6b 
 < fl 1800 (<€ 817) 23 (19.7%) 24 (20.2%) 
 
 fl 1800-fl 2500 (€ 817-€ 1134) 27 (23.1%) 36 (30.3%) 
 fl 2500-fl 4500 (€ 1134- € 2042) 50 (42.7%) 42 (35.3%) 
 > fl 4500 (>€ 2042) 17 (14.5%) 17 (14.3%) 
SES / Education   0.001*b 
 Elementary school  (lower level) 14 (11.5%) 39 (30.5%) 
 
 Secondary education  (intermediate level) 60 (49.2%) 59 (46.1%) 
 Secondary education (higher level) 26 (21.3%) 17 (13.3%) 
 Higher education  (university) 
(table continued on next page) 





(table 1, continued) 
Youth experience 
 
Before 16 year; placed in a children’s home 
or youth detention centre or raised in foster 
homes  
1 (0.8%) 6 (4.7%) 
0.06b 
Brugha number of Life events  
Total score range 0-12 0.53 0.55 0.9a 
Coping  
Avoidant coping range 7-35 17.9 18.2 0.7a 
Task oriented range 7-35 23.8 22.5 0.1a 
Emotion oriented range 7-35 18.7 19.0 0.7a 
SSL-12-I  
Total score of supportive interactions range 
12-48 
31.4 30.3 0.1a 
Every day support range 4-16 11.3 10.8 0.08a 
Social support in problems range 4-16 9.5 9.4 0.7a 
Esteem support range 4-16 10.7 10.2 0.1a 
Loneliness  
Total score range 0-11 2.6 3.5 0.03*a 
 * Statistically significance level 0.05 
 
Results 
The study recruited 164 short-term and 158 long-term benzodiazepine users. In 72 
cases, no SCAN interview could be scheduled in time due to logistical reasons, 
leaving 122 short-term and 128 long-term users with complete data to study. 
Comparing study patients with all short- and long-term benzodiazepine users in the 
practices, short-term users were older (participants > 45 years 63.4% versus 53.8%), 
but otherwise no differences were found.  
 
Analysis (Table 1) 
Caseness, in particular with morbidity diagnosed in two or more diagnostic 
categories, was statistically significantly associated with long-term benzodiazepine 
use. No statistically significant association was found for specific diagnoses. Of the 
psychosocial characteristics, a lower level of education, older age and loneliness 
were statistically significantly associated with long-term benzodiazepine use. No 
statistically significant differences were found for the other independent variables. 
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The multivariate logistic regression showed that the one diagnostic category [odds 
ratio (OR) 2.38; confidence interval (CI) 1.21–4.69], 2–8 diagnostic categories (OR 
3.61; CI 1.40–9.26), avoidance coping style (OR per unit 1.05; CI 1.00–1.10), 
loneliness (OR per unit 1.09; CI 0.99–1.19), lower level of education (OR 2.00; CI 
0.90–4.43) and older age (OR per unit 1.07; CI 1.04–1.09) were related to long-term 
use. The goodness of fit of the model was satisfying (Nagelkerke R2 = 0.2750). 
Interactions and confounders were not found between the different variables.  
 
Discussion 
Psychiatric (co-) morbidity, an avoidance coping behaviour, loneliness, older age and 
lower education were associated with long-term benzodiazepine use compared with 
short-term use. The cross-sectional design implies that we cannot analyse cause– 
consequence relationships. However, comparing long-term with short-term users 
rather than with non-users provides clear suggestions of factors related to long-term 
use. As we controlled for the influence of the prescribing family physician on long-
term use, our findings represent true patient factors.  
Although psychiatric morbidity was more strongly associated with long-term than with 
short-term use (in about half versus a third of the cases), the presence of a ‘formal’ 
DSM-IV diagnosis could not in itself completely explain long-term use.  
Psychological characteristics and coping were interrelated with psychiatric morbidity, 
which has been described.17,18 Nevertheless, loneliness, education level and 
avoidance coping were related in their own right to long-term benzodiazepine use.  
Training practices were over-represented, which may have resulted in a more 
restricted benzodiazepine prescribing routine in the study sample.  
Usually, psychological characteristics, coping and co-morbidity are largely ignored in 
guidelines and recommendations of benzodiazepine use, but our findings point out 
that this characterizes long-term users. There is a lack of evidence of the (long-term) 
effectiveness of benzodiazepines for these features that may underline the 
complexity and vulnerability of these patients. In the absence of further evidence of 
benzodiazepine effectiveness, we recommend caution in starting prescribing 
benzodiazepines, and, when prescribing, regular evaluation of the effects, in 
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Aim: To determine the appropriateness of benzodiazepine prescription: Do the mental 
health problems diagnosed by GPs justify the prescription of benzodiazepines, also 
taking into account the duration of benzodiazepine prescription? 
Method: In a cross-sectional survey of 1813 patients at 32 general practices, the 
appropriateness of benzodiazepine prescription was assessed using two criteria: a 
mental health problem was present for which a benzodiazepine is considered to be 
effective according to guidelines and the prescription was for no longer than 90 days. 
Results: Benzodiazepines had been prescribed to 94 patients (5%) in the 90 days prior 
to the start of the study. In 67% of these patients, no mental health problem was 
present for which benzodiazepines are considered to be effective. In the remaining 33% 
of the patients, a mental health problem was present for which benzodiazepines could 
be effective. Benzodiazepines had been prescribed for too long in most of these 
patients. 
Conclusion:  In a minority of the patients, the prescription of benzodiazepines was 
considered to be appropriate. We recommend that GPs improve their benzodiazepine 
prescription practice using the ESCAPE acronym. 
Keywords:    
 






Benzodiazepines are only considered to be effective for a limited number of specific 
mental health problems (acute insomnia, acute anxiety, alcohol detoxification) and for a 
limited period of time.1-6 Beneficial effects of long-term use have never been 
established. Moreover, long-term use is associated with various adverse health effects 
(cognitive deterioration, dependence, falls and fractures, drug interactions).7-10 
Therefore, the guidelines advise physicians to confine themselves to short-term 
benzodiazepine prescription for a limited group of indications. Contrary to these 
recommendations, a prevalence rate of long-term benzodiazepine use of 0.6-2% was 
found in general practice, depending on the design of the study and the time frame of 
the assessment of use.11 Repeatedly, concern has been expressed about this deviation 
from the guidelines in actual medical practice. Prescribing psychotropics based on the 
best available evidence was considered to be an important quality indicator for primary 
care mental health services by patients as well as professionals.12 
Up to now, adherence to guidelines for benzodiazepine prescription in general practice 
has only been studied indirectly by evaluating patient perceptions of indications, by 
asking general practitioners to reflect about their prescription practice, or by studying 
the responses of GPs on case vignettes.13-15 Two studies reported mental health 
problems in patients who had been prescribed benzodiazepines, but no distinct 
diagnoses were mentioned. One of these studies reported mental health problems in 
half of the patients.16 The other study reported an overt psychiatric diagnosis in 28% 
and a mild psychiatric diagnosis in 52% of the patients who were using minor 
tranquillizers.17 Neither of the studies focused on the duration of benzodiazepine 
prescription. 
In the present study, we analysed the adherence of GPs to benzodiazepine prescription 
guidelines, by relating actual benzodiazepine prescription to the diagnoses made by the 




The study formed part of a larger investigation on the prevalence of mental health 
problems in general practice and the prescription of psychotropics.18,19 We identified 




practice medical files and determined the appropriateness and duration of 
benzodiazepine prescription. The GPs provided psychiatric diagnoses on all these 
patients. These diagnoses were considered to be the diagnoses on which 
benzodiazepine prescription had been based.  
 
Study population 
A total of 4517 subjects were selected at random from the registers of 32 general 
practices in the Nijmegen Health Area and invited to take part in the study by a letter 
from their GP; 2049 (45.4%) of them gave informed consent and 1813 (40.1%) 
completed the study. The survey sample contained fewer subjects aged 55-74 years, 
more subjects aged 25-44 years and more women than the Dutch population. No 
statistically significant differences were found in urbanisation, prescription of 
psychotropic drugs and analgesics between the two populations.20 Psychiatric 
diagnoses were provided by the GPs on all these patients and we had access to 
(psychotropic) prescription data. The GPs had only been informed about the general 
aim of the study, so they were unaware that we were going to relate their 
benzodiazepine prescription practice to the diagnoses they had made. To participate in 
this study, general practices had to have a computerized patient and medication 
registration system. At the time of the study, this was the case in approximately 80% of 
the general practices in the Netherlands. The participating practices were 
representative of Dutch general practice with regard to: practice size, number of GPs 
working at the practice, sex of the GPs and year of registration, total number of working 
hours, percentage of practices with a pharmacy. The only significant difference was the 
higher percentage of general practitioner-training practices among the participating 
practices.11 
The subjects were invited to participate by letter from their general practitioner. In the 
Netherlands, every citizen is registered with a general practitioner (personal list). GPs 
treat the large majority of health problems themselves and are gatekeeper to more 
specialised medical care. Specialists report back to the GP, which results in complete 
data in the medical files at the general practices. 
 





Identification of benzodiazepine users 
In the Netherlands, benzodiazepines are legally classified as prescription only. They are 
defined as the ATC coded groups N05BA, CD, CF and CG.21 On the basis of the 
prescription data registered at the general practices, it was possible to determine all the 
prescriptions written for each subject on each day during the year prior to the interview. 
We selected subjects who had received a prescription for benzodiazepines from their 
GP over the past 90 days. The duration of benzodiazepine prescription could be 
followed retrospectively for 730 days. 
 
Diagnosis of mental health problems by GPs 
The GPs specified which mental health diagnoses they had made during the previous 
six weeks on a pre-constructed list that contained the following mental health problems: 
(1) cognitive disorders (dementia, other psycho-organic disorders), (2) substance-
related disorders, (3) psychotic disorders (schizophrenia, delusional disorder), (4) mood 
disorders (mania or mixed disorder, depressive disorder, other mood disorders) and (5) 
anxiety disorders (generalised anxiety disorder, phobic disorder/panic disorder, 
obsessive compulsive disorder, post-traumatic stress disorder), (6) psycho-social 
problems, (7) sleeping problems, (8) personality disorder, (9) other mental health 
problem and/or (10) indistinct diagnosis 
 
Questionnaires  
The General Health Questionnaire (GHQ-30) was used to describe the general health 
status of this patient group.22 
 
Appropriateness of benzodiazepine prescription 
The first criterion to determine the appropriateness of benzodiazepine prescription was 
to assess whether patients with a prescription had a mental health problem for which 
treatment with benzodiazepines was justified. According to the guidelines, 
benzodiazepines can be prescribed for anxiety disorders, insomnia, alcohol withdrawal 
and as co-medication with antidepressant drugs for mood disorders.1-6 The second 
criterion was to assess whether the duration of benzodiazepine prescription had not 
exceeded the 90 days as recommended in the benzodiazepine prescription 




accordance with the guidelines, when both criteria were met. Any benzodiazepine 
prescriptions that did not meet one of the two criteria were classified as inappropriate. 
 
Results  
A total of 94 (5.3%) out of the 1763 participants had received at least one 
benzodiazepine prescription in the 90 days before the interview. The majority of these 
patients were women (n=88). Mean GHQ-30 score of all the patients who had received 
a prescription was 9.9 (SD 8.9) compared to 4.5 (SD 6.3) in the total study population.  
 
Assessment of criterion 1  
In 63 patients (67%), the GP had not diagnosed a mental health problem for which 
benzodiazepines are considered to be appropriate. Thus, in the remaining 31 patients 
(33%), the prescription of benzodiazepines had been appropriate according to criterion 
1. The diagnoses made by the GPs are listed in table 1. 
 
Assessment of criterion 2  
In the group of 31 patients who had received an appropriate prescription according to 
criterion 1, 27 had received prescriptions for more than 90 days.  
 
Thus, four patients had received appropriate benzodiazepine prescriptions according to 
criteria 1 and 2. The diagnoses made by the GPs are listed in table 1. 
 
In the group who had received inappropriate benzodiazepine prescriptions, four (4%) 
had also been prescribed an antidepressant. 





Table 1. Diagnoses of the general practitioner  
Category general 
practitioner-diagnosis 
Appropriateness of diagnosis 
N = 94 
Duration of prescription in patients 
with appropriate diagnosis  N = 31 
Appropriate  
N = 31 
Inappropriate  
N = 63 
< 90 days  
N = 4 
> 90 days  
N = 27 
 At least one diagnosis 31 6 4 27 
Psycho-organic disorder 0 0 0 0 
Substance related disorder 4 0 0 4 
Psychotic disorders 0 0 0 0 
Mood disorders 8 2 1* 7 
Anxiety disorders 7 0 0 7 
Sleeping disorders 20 0 3 17 
Psychosocial problems 6 2 0 6 
Personality disorders 2 0 0 2 
Indistinct general  









No diagnosis 0 57 0 0 
Cumulation above 100% was possible while more than one diagnosis was possible 
* antidepressant prescribed as well 
 
Discussion  
To our knowledge this is the first study that linked mental health problems diagnosed by 
GPs to the prescription of benzodiazepines to adults in general practice. We found that 
benzodiazepines had been prescribed in accordance with the guidelines in only a small 
minority of cases. The following three problems contributed to inappropriate prescription 
of benzodiazepines: 
[1] A mental health problem had been identified that could warrant benzodiazepine 
prescription, but the benzodiazepine had been prescribed for a too long period. This 
suggested that the psychopathology was still present after a fairly long period of 
benzodiazepine use and that the effectiveness of benzodiazepines in these patients 
should have been questioned. In view of the prevalence of mood disorders and anxiety 
disorders, a substantial proportion of these patients may have benefited from 
antidepressant therapy, such as cognitive behavioural therapy or SSRIs, with 




[2] The GPs had not diagnosed a mental health problem for which benzodiazepines are 
considered to be appropriate and benzodiazepines had been prescribed for too long. 
Other treatments are available and should be considered in these patients. 
[3] A mental health problem was no longer present, but the patients continued to 
receive benzodiazepine prescriptions. It is possible that these patients had a tendency 
towards benzodiazepine dependence. In such cases, benzodiazepines should be 
tapered off and other treatments started if (new) mental health problems emerge. 
Different modalities have been described for tapering off benzodiazepine use.23,24  
In a general population study in the UK, over 90% of the patients who were using 
benzodiazepines mentioned sleeping disorders, anxiety/depression and trauma/ 
epilepsy as the reasons(s) for their GP to prescribe benzodiazepines.13 In a US survey, 
the patient-perceived use of approximately half of the benzodiazepine users 
corresponded with medically recognised use, mainly anxiety-related conditions and 
sleeping disorders.25 We found higher rates of inappropriate benzodiazepine 
prescription. From a more pragmatic point of view, it has been argued that in general 
practice, benzodiazepines can play a role in helping patients to deal with emotional 
distress, even in the absence of any major psychiatric disorder.26 However, given the 
support for evidence-based psychotropic drug prescription, the lack of benefit of long-
term treatment and the potential hazards of benzodiazepine use, this point of view can 
be questioned. 
 
Our study design had a number of limitations. Its retrospective nature and the relatively 
small number of patients may have led to underestimation of inappropriate 
benzodiazepine prescription, particularly in the group aged 55-74 years who were 
under-represented in our population sample. As patients of over 74 years of age were 
not included, it remains uncertain whether the findings also apply to this important group 
of benzodiazepine users. Our analysis only distinguished between short-term and 
long-term benzodiazepine use. Earlier studies have also incorporated intermittent use.16 
As the GPs were unaware that we were going to relate their benzodiazepine 
prescription practice to their diagnoses, the influence of the Hawthorne effect can be 
eliminated. 
 





The magnitude of inappropriate benzodiazepine prescription in our study was higher 
than that of prescriptions for a wider range of health problems.27 Research has shown 
that patient-related factors, physician-related factors and management-related factors 
contribute to benzodiazepine use.28-32 Firstly, it should be realized that most users of 
benzodiazepines are very satisfied with the drug: they are not aware of any side-effects 
and do not fear the risk of dependence.16 This situation may stimulate patients to 
request more benzodiazepine prescriptions and GPs to comply with these requests. 
However, drug dependence may play an important role in these feelings of satisfaction. 
Secondly, in some of the patients, the symptoms and problems seemed to be 
treatment-resistant, which may have given the GP the impression that the only option 
was to continue the benzodiazepines.33 GPs should therefore not lose sight of the 
potential harm in the absence of benefits and try to confine their prescription of 
benzodiazepines.  
 
In pursuit of this, GPs may receive more support from their patients than would 
generally be expected. It has been found that the majority of elderly long-term 
benzodiazepine users would like to discontinue their benzodiazepine use, or they are 
willing to consider alternatives or educational sessions on insomnia.28,34  
 
Several strategies have been developed to improve the quality of drug prescription. 
Audit and feedback strategies, collaboration in professional groups and educational 
outreach visits can be effective to improve professional practice and the quality of 
prescription behaviour.35,36 
 
Although benzodiazepines have been available for more than 40 years, evidence-
based procedures to improve prescription quality are few and far between. Some 
intervention strategies have also been evaluated with respect to the prescription of 
benzodiazepines. Reminder cards had a limited effect.37 It seems worthwhile to 
evaluate the effects of other strategies.23 A recent review on changing behaviour in 
health care has concluded that plans for change should be based on characteristics 
of evidence, barriers against and facilitators for change.38 Our study supports the 
notion that there is a need to improve benzodiazepine prescription. More insight is 




In the meantime, we recommend that GPs improve their benzodiazepine prescription 
practice by means of the ESCAPE acronym: 
Evidence-based reason to start prescribing a benzodiazepine 
Short-term prescription and set end-point  
Check effectiveness of benzodiazepine treatment 
Apply active weaning intervention 
Propose other treatment options 
Evaluate effectiveness of new treatment  
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Purpose: To evaluate how the variation in the number of long-term benzodiazepine (BZ) 
users between general practices was influenced by socio-environmental-patient-related 
factors, patient characteristics, GP-related factors and general-practice-related factors. 
Methods: A cross-sectional observational design was used. Variation in the long-term 
prescription of BZs in general practice was studied using data from electronic patient records 
and medication files at 32 general practices in the Nijmegen region (the Netherlands). Social-
environmental-patient-related characteristics were derived from Statistics Netherlands. 
Pearson correlations, univariate and multivariate multilevel techniques were used to analyse 
the data. 
Results: A ten-fold, statistically significant, difference was found in the number of long-term 
prescriptions for benzodiazepines between the general practices. Long-term BZ prescription 
was related to a) the provision of large quantities of tablets on the first benzodiazepine 
prescription b) the utilization of a broad range of benzodiazepine types by the GP c) patient 
gender (female) d) more advanced age and e) social-environmental-patient-related 
characteristics. 
Multilevel analyses showed that 28% of the total variance in long-term BZ prescription was 
explained by general-practice-related factors and patient-related factors, divided into 
4.6%(out of 6.2%)practice-related factors and 23.4%(out of 93.8%)patient-related factors. 
Conclusions: Social deprivation factors were closely related to long-term benzodiazepine 
use. We recommend that GPs be alert to these effects. Tools are needed to help patients to 
cope with the (social deprivation) problems they encounter in daily life. 
Keywords: benzodiazepine, general practice variation, prescription behaviour, cross-
sectional study 
 





Benzodiazepines were introduced in the nineteen sixties as a replacement  for 
barbiturates. Later, prominent issues became apparent particularly in long-term 
users: the risk of dependency and addiction1, the risk of falling and accidents2 and 
the negative impact on cognitive function3;4. Despite guidelines that aim to confine 
benzodiazepine prescription to the short-term, long-term use is an ongoing problem 
in most countries, judging from  prescription rates of 2% in general practice 
populations5 reported in the literature. However, there are large differences in the 
number of long-term users between general practices6. As general practitioners 
(GPs), can in essence be expected to share  the same professional values, other 
factors than their prescription behaviour might influence long-term benzodiazepine 
use. Anderson and Mooney7 stated that part of the explanation for inter-practice 
variation lies in differences in the application of medical interventions to specific 
social, or historical or cultural settings. This underlines the multifactorial nature of 
inter-practice variation. However, most studies that analysed (long-term) 
benzodiazepine use focused on one single explanatory factor. Groenewegen8  found 
that benzodiazepine use was related to the socio-environmental-patient-related 
factors. Cormack9 identified the importance of the attitude of the GP: frequent 
prescribers believed that writing a prescription saved consultation time and they 
assumed that the patients expected to receive a prescription. In an earlier study10;11 
we have found that patient risk factors for long-term use were more advanced age, a 
history of mental health problems, chronic (physical) illness that involved frequent 
referrals to hospital specialists and lower perceived health status. However, we have 
little insight into how these factors are interrelated, which hampers the development 
of effective intervention strategies to prevent long-term benzodiazepine use.  
Therefore, this study analysed the inter-practice variation in long-term 
benzodiazepine use on the basis of  demographic patient characteristics, socio-
environmental-patient-related characteristics, GP-related characteristics and practice-
related characteristics separately as well as in combination. Our underlying concept 
was that GPs work according to professional values that in this case were 
summarised in guidelines on the prescription  of benzodiazepines. The application of 
these professional values means that  GPs respond to their patients’ needs and 




environmental patient characteristics. The result of this interaction is that the patient 
receives a benzodiazepine prescription.   
 
This general practice study addressed the question: To what extent can inter-practice 
variation in long-term benzodiazepine prescription be explained by the above-
described patient and GP-related characteristics? 
    
Data and methods 
 
The patient and medication data analysed in this study were obtained from the 
electronic medical records at  32 general practices (52 GPs) in the southeast of the 
Netherlands. These practices had participated in a population survey on 
psychopathology, the so-called Nijmegen Health Area project-25;10-12. In accordance 
with the Dutch health insurance system, every inhabitant is registered at a general 
practice, thus our general practice population was representative of the Dutch 
population. 
Data from Statistics Netherlands13 were used to characterise the socio-environmental 
-patient-related characteristics. In addition, we  interviewed the GPs to obtain data on 
practice-organisation-related characteristics.  
Recruitment and data collection 
General practices with an electronic patient and medication registration system were 
eligible to participation in the study. At the time of this research, 80% of the practices 
were equipped with these systems.  We approached 64 practices  and 32 of them 
agreed to participate. The main reason for refusal  was involvement in other 
research. Details of the approach and representativeness of the general practices 
and population sample have been described elsewhere1;5. One practice was 
excluded because the electronic prescription data were incomplete. Thus, the 
prescription data recorded during one-year at 31 general practices formed the basis 
of this research. A total of 80,831 patients were listed at these 31 general practices. 
Definition of a benzodiazepine  user  
Benzodiazepine users were patients who had received benzodiazepines on 
prescription from their GP5. Dutch health insurance guidelines state that 
benzodiazepines (defined according the standardised WHO classification system for 




drugs, using the Anatomical Therapeutic Chemical classification-indexa groups 
N05BA, CD, CF and CG14) can only be prescribed by a physician.  
We defined a long-term benzodiazepine user as a patient who had received 
benzodiazepines on prescription for  180 days in one year5;10. On the basis of data 
extracted from the prescription files, we calculated i) the percentage of (long-term) 
benzodiazepine users at each practice and ii) the proportion of long-term 
benzodiazepine users in the total group of benzodiazepine users recorded in the one 
year study period. 
General-practice-related-characteristics 
 Information on the following practice characteristics were obtained by interviewing 
the GPs: type of practice (solo, duo, group), number of GPs within the practice, 
gender of the GPs and involvement in GP training (‘training practice’). The electronic 
medical records at each practice were used to calculate the total number of patients 
per full-time equivalent GP, the percentage of female patients aged 18-75 years and 
the percentage of patients aged > 50 years.  
Practice-professional-prescription characteristics 
To describe the benzodiazepine prescription behaviour at each general practice, we 
collected data from the electronic medication records. These comprised the 
Anatomical Therapeutic and Chemical code, instructions for dosage and duration of 
use. We categorised the benzodiazepine prescriptions into first prescriptions and 
repeat prescriptions15. From the first as well as the repeat prescriptions, we 
calculated: 1) the number of days of BZ use covered by the prescription (e.g. “60 
tablets, one to be taken, 3 times a day” represents 20 days of BZ use); 2) the defined 
daily dose equivalent (DDD equivalent) by dividing the prescribed daily dose by the 
DDD14-16 of the benzodiazepine17  and 3) the total DDD by dividing the prescribed 
daily dose (PDD) by the DDD multiplied by the number of days of BZ use covered by 
the prescription17. The instructions for use written on the prescriptions were classified 
into specific instructions (e.g. 3 times a day), less specific instructions (e.g. 1 to 3 
times a day) and non-specific instructions (take as needed). The type of drug was 
classified as 1) a hypnotic or anxiolytic and we also recorded 2) its half-life based on 
a cut-off point of 24 hours, i.e. less than 24 hours, or 24 hours or longer. We also 
                                                     




counted the number of different types of benzodiazepine (number of ATC codes) 
used at each practice.  
Socio-environmental-patient-related characteristics  
In this study, we used the following information per post code as an indication of the 
level of social and material deprivation: the percentage of people with a low income, 
the percentage of unemployed, the percentage of minorities and the percentage of 
single households. These data were derived from the Statistics Netherlands13;18 (SN; 
see table 2) database. In addition, we used  the “address density” (number of 
households per km2) and  ‘number of inhabitants per post code’ as a measure of 
urbanisation. Post code information was combined with the patient information from 
the general practice database.  
All the survey data were linked to a unique individual patient number. This number 
was linked to the post code to achieve patient anonymity. 
 
Analyses 
Practice prescription percentages were calculated and standardized for age and 
gender of the Dutch population18. 
Pearson correlation coefficients were calculated to investigate the extent to which 
patient-related characteristics, general-practice-related characteristics, professional-
prescription characteristics and the socio-environmental-patient-related characte-
ristics could explain differences in benzodiazepine prescription rates.  
Owing to the hierarchical structure of our study (patient nested within practice) and 
the dichotomous outcome variable (long-term benzodiazepine user yes/no) we used 
univariate and multivariate multilevel logistic models (the SAS macro Glimmix19). In 
our multilevel analysis, the total variation in prescription activity was separated into 
two parts: patient-related and practice-related factors. 
When the factors identified in the univariate analysis  had also been reported in the 
literature,8;10;11 they were entered into the multivariate model.  Explained variance 
was calculated according to Snijders & Bosker 199916. 
 
Results   
The non-standardised overall prevalence of benzodiazepine users per practice varied 
from 4.4% to 17.3%. After standardisation for age and gender of the practice 




population, these rates were 5.0% to 18.4% (table 1). The standardised proportion of 
long-term benzodiazepine users  varied from 8.7% –35.7% between the practices 
(table 1). 
 






% Overall BZ 
Standardised 
% Overall BZ  
Non-
standardised  







All practices mean 8.6 9.2 1.8 2.1 22.3 
SE 0.5 0.6 0.2 0.2 1.2 
Limit 4.4 - 17.3 5.0 - 18.4 0.4 – 4.4 0.4 – 4.4 8.7 – 35.7 
Nijmegen mean 9.7 11.2 2.2 2.8 25.3 
Region mean 8.0 8.1 1.6 1.7 20.7 
T-test 2.3 9.3 3.0 17.9 3.6 
P 0.14 0.005 0.10 0.0002 0.07 
Non-standardised % Overall BZ = % benzodiazepine users in a year  according to the electronic  
patient file. 
Standardised % Overall BZ =% benzodiazepine prescription users in a year corrected for the age 
and gender distribution in the Dutch population. 
Non-standardised % Long-term BZ =% long-term benzodiazepine users in a year according to the 
electronic patient file. 
Standardised % Long-term BZ =% long-term benzodiazepine users in a year corrected for the age and 
gender distribution in the Dutch population according to Statistic Netherlands. 
Standardised proportion % Long-term BZ = Standardised % Long-term BZ / Standardised % Overall 




Table 2 presents the descriptive figures of the general-practice-related 
characteristics, professional-prescription characteristics and the socio-environmental-
patient-related characteristics. Compared to the national average, the practices that 
participated in our study had more female GPs, a larger proportion of group practices 





Table 2: Descriptive statistics of general practice characteristics (N=31) professional prescription 
characteristics (n=48,046) and socio-environmental characteristics  (n=80,513) 
 
Characteristics  N %  Min. Max. Mean National i 
(1997) 
General Practice organisation related  
Gender GP: male only  20 64.5    81.8% 
General practitioner training   12 38.7     
Practice type       
Solo (or only 1 FTEii practice) 19 61.3    68.5% 
Duo  8 25.8    23.2% 
Group  4 12.9    5.2% 
Number of GPs in the practice   1 4 1.6  
1 18 58.1     
2 7 22.6     
3 5 16.1     
4 1 3.2     
Workload  Population size   1428 9697 3580  
Population size / FTEii   1428 4153 2639  
% female patients   45.6 69.3 50.6 Mean 50.6 
% elderly patients > 50 years   3.6 36.6 25.4  
Professional Prescription / practice vi 
Duration covered by the first prescription (in days)   8.3 36.5 14.5 - 
DDD equivalents on the first prescriptioniii   0.6 1.1 0.7 - 
Total DDD on first prescription   5.0 20.4 10.1 - 
% Non specific instructions / patientiv   0.0 30.8 4.6 - 
% Non and less specific instructions / patientv   0.0 0.8 0.3 - 
% Sedative used    0.4 0.8 0.6 - 
% BZs with long half life   0.1 0.4 0.2 - 
Number of ATC codes used   4.0 18.0 9.6 - 
Neighbourhood  
Urban (city of Nijmegen) 11 35.5     
High address density/km2vi   167 2687 1127  
Number of inhabitants/ post codevi   2227 11201 6278  
% Low income vi   34.0 51.5 41.7  
% High income vi   11.1 29.4 18.0  
% Non-active persons (age 15-64 years) vi   11.6 33.8 21.9  
% Non-family-units vi   10.8 50.8 23.9  
% Minorities vi   0.0 7.7 3.3  
I  NIVEL (Netherlands Institute for Health Services Research) www.nivel.nl/beroepenindezorg > huisartsen > functie en geslacht 
(1970-2004) or praktijkvorm (1991-2004) 
ii  FTE- full time equivalent 
iii (Prescribed Daily Dose/ Defined Daily Dose= DDD equivalent) 
iv  non specific instructions, for example take as usual 
v  non and less specific instruction, for example 1 till 3 tablets a day 
vi Value is the aggregated variable on a practice level (or practice mean value) 




Univariate relations between the long-term benzodiazepine users and the various 
characteristics were analysed in two different ways: on a practice level ( percentage 
of long-term benzodiazepine users per practice) and on a patient level (patients who 
had received long-term benzodiazepine prescriptions vs patients who had not as the 
dependent variable).  
 
Table 3 presents the findings on a practice level, with the corresponding Pearson 
correlations.  Table 4 presents the findings on a patient level, with the corresponding 
Odds Ratios. 
 Patient-related social and material deprivation factors were significantly related to 
long-term BZ use on a practice level as well as on a patient level. 
Pearson correlations (table 3) between the practice characteristics did not show any 
relation with general-practice-organisation factors, but there were  relations with 
professional-prescription characteristics. In the univariate analyses (table 4) on 
patient characteristics, we found a significant relationship between long-term 
benzodiazepine use and practice involvement in GP training, patient gender (female) 
and more advanced age.  
  
Owing to the hierarchical structure of the study (patient nested in practices), we 
tested several models to reach the highest statistical level of explained variance. We 
started with a 0-model that only contained our dependent variable to search for the 
distribution of variance over the two levels. This resulted in 93.8% explained variance 
on a patient level and 6.2% on a practice level. Then we tested a model with  the 
professional-prescription characteristics (number of days covered and DDD 
equivalent on the first prescription and the number of different ATC –codes used by 
the GP). This resulted in 4.5% explained variance on a practice level and 0.4% on a 
patient level. A model with the practice-population characteristics (age and gender) 
alone resulted in 1.4% explained variance on a practice level and 23.9% on a patient 
level. A model with the socio-environmental-patient-related characteristics alone 
resulted in 0.9% explained variance on a practice level and 0.5% on a patient level. A 
final model with professional-prescription characteristics, practice-population 
characteristics and socio-environmental-patient-related characteristics together, 




(out of 93.8%) on a patient level. Interaction was found between the separate 
variables:  the sum of the individual components (4.5+0.9+1.4=6.8) was larger than 
the 4.6% explained variance in the final model that included all the variables. 
  
Table 3: Relations between benzodiazepine users and general practice characteristics, practice 
professional prescription characteristics and socio-environmental characteristics (Pearson 
correlations, N=31) 
Characteristics Standardised 








General Practice organisation related 
General Practitioner training -.23 -.18 -.21 
Practice type: solo/duo/or group .14 .08 .11 
Number of GPs working at the practice .14 .08 .13 
 
Workload 
Population size .02 -.01 -.05 
Population size/ FTE -.08 -.06 -.15 
% female patientsii .10 .00 .13 
% elderly patientsii -.25 -.08 -.26 
Professional Prescriptions / practice II 
Duration covered by the first prescription (days) .36 * .30 .20 
DDD equivalent on the first prescription .12 -.02 .13 
Total DDD on first prescription .44 * .32 .25 
% Non specific instructions -.22 -.11 -.18 
% Non and less specific instructions -.09 .01 -.15 
% Sedative prescriptions .01 -.15 .13 
% BZs with long half life .41* .11 .54* 
Number of ATC codes  .53 * .29 .48* 
Socio-environmental factors II 
City/region of Nijmegen .62** .33* .49* 
High address density/km2 .57* .30 .43* 
Number of inhabitants/ post code .23 -.05 .33 
% People with low income .74** .56* .43* 
% People with high income -.63** -.48* -.36* 
% Non-active persons .69** .36* .55* 
% Non-family units .50* .33 .31 
% Ethnic minorities .65** .40* .50* 
i BZ = Benzodiazepine users 
Ii = Value is the aggregated variable on a practice level (or practice mean value) 
* Significant P < 0.05 
** Significant P <0.001 




Table 4: Odds Ratios for long-term benzodiazepine use and the individual characteristics (31 practices 
and n=80525 people) 
Characteristics Odds Ratioii Confidence 
Interval 
p 
General practice organisation related     
General Practitioner training 0.64 0.46-0.83 0.007 
% female patients 0.98 0.94-1.02 n.s. 
% elderly > 50 years 1.02 1.00-1.04 0.05 
Professional Prescription / practice    
Duration covered by the first prescription 1.05 1.01-1.08 0.005 
Total DDD on the first prescription 1.07 1.03-1.11 <0.001 
% BZs with long half-life 1.02 0.99-1.06 n.s. 
Number of ATC codes used per practice 1.12 1.07-1.16 <0.0001 
Socio-environmental     
Gender (female) 1.79 1.62-2.00 <0.0001 
Age per year 1.08 1.07-1.08 <0.0001 
Urbanisation Nijmegenii 1.30 0.91-1.86 n.s 
% People with low incomeii 1.03 1.01-1.04 <0.0001 
% Non-active persons (15-64 years)ii 1.03 1.02-1.04 <0.0001 
% Non-family unitsii 1.00 0.99-1.00 n.s. 
% Ethnic minoritiesii 1.06 0.99-1.14 n.s 
i= Individual value 
ii = Calculated using univariate multilevel analysis (SAS Glimmix) 
 
Table 5: Variables that contributed  to the explained variance in long-term benzodiazepine use 
(multilevel model)   
Models Overall (%) Patient level (%) GP and practice level (%) 
Explained variance  goal:(%) 
0-model 







Final model with: patient age & 
gender, socio-environmental 








Unexplained variance  70.4 1.6 
Explained variance when single group was entered into the multilevel model  
1) Patient age and gender  25.3 23,9 1,4 
2) Socio-environmental  1.4 0.5 0.9 





Summary of the main findings 
In this study on practice populations (18-75 years), we found a ten-fold difference in 
the prevalence of long-term benzodiazepine users between the general practices. 
There was also an important but limited (6.2%) effect of practice characteristics on 
long-term benzodiazepine use. Most of the variance could be explained on a patient 
level, by the age and gender of the patient. Within the final multilevel model, our 
practice characteristic variables (professional-prescription characteristics, practice 
population and socio-environmental-patient-related characteristics) explained nearly 
75% (4.6% out of 6.2%) of the variance in practice factors. However, the analysis 
showed clearly that the prescription behaviour of the GP was only one – and not the 
strongest – factor in the total equation. We therefore  concluded that the influence of 
the GP on long-term benzodiazepine use should be viewed in the context of patient-
related factors and their socio-environmental circumstances.  
Socio-economic deprivation factors and the age and gender composition of the 
population were identified as important determinants. Thus we hypothesize that a 
benzodiazepine prescription is written under the influence of these patient-related 
factors and that GPs tend to prescribe BZs to help minimize the complaints in the 
short-term, without paying sufficient attention to the risks of prescribing BZs in the 
long-term. 
  
Strengths and limitations of this study 
The data analysed in this study were collected in 1997, which must be taken into 
consideration when translating the results into current practice. However, important 
guidelines that define good benzodiazepine prescription behaviour in general 
practice and particularly discourage the long-term use of BZs, have not changed 
essentially since 199720-22. In addition, between 1997 and 2005, benzodiazepine 
prescriptions in the Netherlands have seen only a 0.4% increase in number in 
conjunction with a mean decline of 0.8% in DDD(Foundation for Pharmaceutical 
Statistics23 and LINH24). Therefore we are confident that our findings are applicable 
to current general practice.  
This study took place in a distinct region of the Netherlands, under the regulations of 
Dutch health care, which means that we must be cautious about generalising our 




findings to other GPs who work under other health care systems. Nevertheless we 
feel that  our findings have broad implications, because most countries restrict the 
prescription of benzodiazepines to qualified doctors and the prevalence of long-term 
benzodiazepine users in this study was very similar to that in many other 
countries15;25-32. Therefore, it seems justified to generalise our findings to countries 
with comparable social-economic standards, health systems and benzodiazepine 
prescription rates.  
Although we were able to survey a substantial population of patients and 31 general 
practices, larger samples might have enabled more in-depth analyses of inter-
practice variation. Possible limitations were that there were more female GPs and 
more group practices at  the 31 practices than in the national figures. However, there 
is a current national trend towards more female GPs and group practices. Thus, this 
study may have captured a view of general practice that reflects the near future. 
To analyse socio-environmental-patient-related characteristics, we used post-code-
related data, i.e. information on an aggregated post code level. This made it 
impossible to distinguish between social and material deprivation on a individual level 
and a population level. 
To analyse professional-prescription characteristics, we had to use practice 
information rather than individual GPs prescribing. This did level-out intra-practice 
prescribing variation. 
 In our Pearson analysis, we pooled the micro-level (patient) data to the macro-level 
(socio-environmental) and this aggregation might have caused loss of information on 
a patient level. However, a crucial aspect in this study was the cross-sectional 
design. Consequently, it was not possible to draw any causal conclusions. 
Nevertheless, we found that the presence of social deprivation led to more long-term 
benzodiazepine prescriptions, but there were differences in the number of long-term 
prescriptions between the general practices. Obviously,  social deprivation problems 
are difficult for GPs to cope with as solitary care providers. It is essential to gain 
greater insight into the dynamics of a broad range of different factors in order to 
achieve effective guidance of benzodiazepine prescription and the prevention of 
long-term use. The contribution of practice factors was probably underexposed in this 




use benzodiazepines. If we restrict our focus to the older age group  (45 years and 
older), the contribution of practice factors would probably be much larger. 
 
Comparison with the literature 
The results of our study fit well with the high prevalence (40-97%) of benzodiazepine 
dependence reported by Kan1 and the difficulty of stopping benzodiazepine use when 
the is dosage is high, as mentioned by Oude Voshaar 33. It is conceivable that a GP 
who prescribes larger numbers of tablets or writes prescriptions for longer durations 
can induce BZ dependence and consequently long-term use.   
Groenewegen8 concluded that socio-environmental effects were partially determined 
by the  age and gender of the population. Thus the prescription behaviour of GPs 
might be more important than social deprivation8;34. Our analysis confirmed the role 
of prescription-behaviour, but its impact was lower than that of socio-environmental 
and population characteristics. The combination of contributing factors was in line 
with the findings in other studies35-37. Therefore, it is very  important to look at all the 
interactions around long-term benzodiazepine use. Qualitative factors of prescription 
behaviour36 should be taken into account, as well as the challenges facing GPs and 
the needs of patients who have to cope with the health and social problems that 
underlie the BZ prescriptions. If certain factors are overlooked, then attempts to 
monitor and measure the quality of care38 related to benzodiazepine prescription will 
be incomplete.  We agree with Carthy39 that without support, monitoring and 
encouragement are necessary to forge better decision partnerships, or some 
prescription behaviour will remain suboptimaly.  
 
Implications for future research and clinical practice 
Our study implicated that interventions to rationalise the prescription of 
benzodiazepines by GPs will be effective. More effect can be achieved by taken  the 
multifactorial determination of long-term benzodiazepine use into account.  Until now, 
strategies to change long-term benzodiazepine prescription have mostly intervened 
on an individual GP level or patient level. New strategies must incorporate GP-related 
factors as well as the patient-related factors. Additional research should focus on the 
underlying health problems in vulnerable populations. In this context, a concerted 
medical and political approach is needed to revise the adverse effects of long-term 




benzodiazepine use. Intersectorial activities should be to developed whose final goal 
is to increase the empowerment of vulnerable patients and consequently improve 
their quality of life.  
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Objective. To explore the feasibility of a risk indicator to alert the general 
practitioner (GP) to imminent long-term benzodiazepine prescription and its 
incorporation into the electronic patient record system.  
Methods. A quasi-experimental study was conducted at 21 practices with an 
electronic patient record system and at 11 reference practices over a three-year 
period.  The main outcome measures were:  the perceived effect on the prescription 
behaviour of GPs, the applicability of the risk indicator to patient care and its 
feasibility, the number of new long-term benzodiazepine users in the study period.  
Comparisons were made between data obtained before and after the introduction of 
the risk indicator and between the intervention and reference practices. 
Results. The risk indicator was used 648 times when the GPs were considering 
new benzodiazepine prescriptions. In 22% of the cases, the GPs reported an 
influence on their prescription behaviour: the higher the risk score, the greater the 
influence on the prescription behaviour.  No technical problems occurred. Insufficient 
consultation time and software problems counteracted the otherwise positive 
experiences with the risk indicator. We did not find any  statistically significant 
differences in the total number of new long-term benzodiazepine users between the 
practices that used the risk indicator and those that did not.   
Conclusions. GPs adjusted their benzodiazepine prescription behaviour when alerted 
by a high risk indicator score. Effects on a patient level should be studied 
prospectively with a more sophisticated risk indicator.  
Keywords: long-term benzodiazepine use, general practice, feasibility study, 
prevention 





A substantial proportion of general practice populations are long-term 
benzodiazepine users despite the advice in professional guidelines on its short-term 
(< 4 weeks) prescription only1. In 1971 and 1981, Balter2,3 studied long-term 
benzodiazepine use in European countries and the USA. International variation was 
found from 0.5% (Sweden) to 5.8% (Belgium), with the Netherlands (1.7%) and the 
UK (3.4%) in intermediate positions. The main reasons to restrict benzodiazepine use 
to the short-term are loss of effectiveness4,5 and adverse side-effects (dependency6, 
addiction, negative impact on cognitive function7, risk of falls8 and traffic 
accidents9,10). In Europe and the USA, benzodiazepines can only be prescribed by a 
physician. Owing to  the role of general practitioners in the continuity of care, they 
often occupy a central position in the continuation of benzodiazepine use. This 
implies that interventions to reduce long-term benzodiazepine use should be directed 
at general practitioners. Until now,  such interventions have included the use of quit 
brochures11-13, feedback to GPs about their  actual prescription behaviour14,15, 
continuing medical education programmes16,17 and the promotion of best practices.  
Interventions directed at the prevention of long-term benzodiazepine prescriptions 
have received with enthusiasm, but none have been studied extensively18.  
Long-term benzodiazepine use is determined by a broad range of factors,19-22 
including the patient's  age and gender 23-25,   health beliefs26, cultural background 27,  
(co-)morbidity28,  socio-economic background 29 and GP  characteristics 30.  The role 
of the GP in long-term benzodiazepine use has been confirmed in of our previous 
studies31. The next step was to conduct this follow-up study that focused on the 
feasibility of prescription behaviour risk monitoring at general practice. Previous 
papers32-34 have described the development of a risk-indicator profile to predict the 
likelihood that individual patients will become long-term benzodiazepine users. By 
incorporating a risk indicator into the electronic patient record system at general 
practices, it was the intention to alert the GP to the level of risk  on every occasion 
that a benzodiazepine prescription was under consideration  (see figure 2).  This 
computer-based risk indicator was developed to help GPs identify patients at risk of 
long-term benzodiazepine use, before a de-novo benzodiazepine prescription was 





acceptance by GPs and its effect on the incidence of new long-term benzodiazepine 
users in the practice populations. 
 
Materials and Methods 
Design 
A quasi-experimental study was conducted to explore the effect of the risk indicator 
on the benzodiazepine prescription behavior of GPs. Comparisons were made 
between before – after prescription data and between the study practices and a 
group of reference practices34.  Outcome measures were the opinions of the GPs 
about the  risk indicator, their actual use of the risk indicator in patient care and the 
number of new long-term benzodiazepine users after its introduction.  The electronic 
patient records also reflected the effect of the risk indicator on the prescription 
decisions of the GPs (see figure 2). The medication files in the electronic patient 
records provided information on long-term benzodiazepine users in the 18 months 
before and after the introduction of the risk indicator. At the end of the study period, 
the GPs were interviewed about the applicability and suitability of the risk indicator. 
 
Subjects and practices  
Approval for the study was received from the medical ethical review board of the 
University Medical Cente Nijmegen (the Netherlands). 
The risk indicator was incorporated into the two main software packages for 
electronic patient records: MicroHIS and Promedico.  We identified all the general 
practices within a distance of 100 km from Nijmegen that were using these systems. 
Then we drew a random sample of 120 general practitioners who were working at 
109 practices. A total of 28 practices had to be excluded because they had 
participated in the previous research35, or were involved in other (benzodiazepine) 
research, or there were practical problems (no GP; inability to operate the electronic 
patient record system) (figure 1). Ultimately, 29 practices (with 32 GPs) agreed to 
participate. The main reason for refusal was time constraints (23).   
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109 general practices 
(120 GPs) 
 
28 general practices 
79 general practices eligible 
Total 50 general practices 
6 illness / pregnancy 
6 other research 
23 time constraints 
11 no specific reason 
4 no interest in research 






Outcomes were: (1) the effect of the risk score on the GPs’ decisions to prescribe 
benzodiazepines; (2) the GPs’ opinions about the suitability and applicability of the 
risk indicator in everyday practice and (3) the number of new long-term 
benzodiazepine users. Comparisons were made between the number of patients who 
received long-term benzodiazepine prescriptions in the 18 month periods before and 
after the introduction of the risk indicator (study period 1998 to 2001). Similar data 
were collected from the LINH research network practices34 for reference purposes 
(e.g. secular trends). An additional analysis was performed on the effects of the risk 
indicator on benzodiazepine prescription behaviour, corrected for practice variation, 
to measure the GPs’ adherence to the actual use of the risk indicator.  
 
Instructions for the general practitioners 
The GPs received written instructions about how to  install the software and use the 
risk indicator (figure 2). Each time a new benzodiazepine prescription was under 
consideration, the GPs were asked  to use the risk indicator to calculate a risk score 
from 0 to 100. This gave an indication of the patient’s risk of becoming a long-term 
user (high score= high risk). No additional instructions were given regarding 
benzodiazepine prescription behaviour. 
 
Benzodiazepine prescription data 
Benzodiazepine prescription information was obtained from the electronic patient 
records, using the same methodology as that in previous studies.31-32,35 
A new benzodiazepine user was defined as a patient who received a benzodiazepine 
prescription, but did not have a history of  benzodiazepine prescriptions during the 
previous 6 months. 
A new long-term benzodiazepine user was defined as a new benzodiazepine user 
who had received prescriptions for benzodiazepines for at least 180 days out of the 
365 days since the first prescription (in conformity with earlier studies31,35). When 
follow-up was less than 240 days, but more than 210 days, this duration criterion was 
modified into 150 days or more, for a follow-up of  210-180 days, this was modified 
into 120 days or more. 
 




Figure 2.  Screenshot of the risk indicator  





Baseline descriptive statistics were calculated using the SAS package and SPSS 
package. 
A repeated measures GEE analysis (SAS proc genmod) was used to calculate the 
number of new long-term benzodiazepine users before and after the introduction of 
the risk indicator per 1000 patients/year. The results were compared to the findings in 
the reference group. 
Owing to the clustered structure of the data (patients within practices), a multilevel 
analysis was carried out using SAS prox glimmix36 to determine the extent to which 








A total of 29 practices were selected, but eight had to be excluded:  three because of 
unresolved computer problems and five because of major staff problems. This 
resulted in 21 study practices.  
 
Locations of the study practices were eight in a highly urbanised region ( address 
density > 1500/ km2), 11 in the country (address density < 1000/ km2) and two in sub-
urbanised areas37. 
Table 1 presents the demographic characteristics of the study practices and 11 
reference practices. The study practices had 61,768 patients, compared to  42,182 at 
the reference practices. The percentages of female patients (aged 18-75 years) and 
patients of over 50 years were representative of the Dutch population.  
 
Table 1: Demographics of the study practices and LINH practices in the total study period, 
before and during risk indicator use  
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13.8-69.1 0-9 10.5-63.2 0-7.5 
Reference 
practices 


























25.3-58.7 0.4-4.3 21.8-57 0-3.3 
. 
 
Use of the risk indicator by the GPs and its effect 
Over the 1.5-year study period, 2148 patients received their first prescription for 
benzodiazepines and 1229 risk indicator forms were filled out. Strict application of our 




definition of new benzodiazepine users meant that  648 forms could be used in the 
analysis (figure 3).  
In 497 patients, the risk score was  50, which indicated a low risk. In 151 patients, 
the risk score was > 50, which indicated a high risk. 
The GPs reported that the higher the score, the more influence it had on their 
prescription decision.  
 




















Actual prescription decisions 
In 140 cases  (22%), the GPs reported that the risk score had influenced their 
prescription decision. Occasionally,  this had resulted in them abstaining from 
prescribing benzodiazepines. However in 81 cases, the GPs had been strongly 
inclined  to prescribe as usual. 
 
648 risk indicators filled out  for new benzodiazepine users 
5 cases: no benzodiazepines prescribed 
and/or other therapy given 
62 cases: fewer benzodiazepines prescribed 
and/or other therapy given 
66 cases:  usual number of benzodiazepines 
prescribed and/or other therapy given 
354 cases: medically acceptable motive  
81 cases: explicit request from the patient 
49 cases: the only option according the GP(no 
specific medical grounds) 
24 cases: other  reasons 
No influence on the GP’s decision, because 
N=508 









Figure 4. Flow chart of completed Risk indicator forms in relation with the new long-term 
benzodiazepine users  
 
 
1229 risk indicator forms filled out 
1024 complete risk indicator forms 
205 risk indicator forms had incomplete data 
648 risk indicators forms for   
new benzodiazepine users 
376 cases had used benzodiazepines in the 
previous 6 months  
16 cases: no benzodiazepine prescriptions 
issued 
73 cases: lost to follow-up (out-of practice) 
126 cases: follow-up too short (filled out at 
end of study period) 
67 cases: had used benzodiazepines in the 
previous 6 months  
366 new benzodiazepine users 
13 new long-term benzodiazepine users 353 short-term benzodiazepine users 




Opinions of the GPs about the feasibility of using the risk indicator 
There was consistency between the GPs’ reports of risk indicator use obtained during 
the interviews and the data recorded in the electronic patient records. 
According to 17 GPs, the instructions for use had been clear; two of them reported 
that the risk scores had improved their decision-making regarding benzodiazepine 
prescription in general. Problems with using the risk indicator during consultations 
were reported by six GPs. (1) the risk indicator form had not appeared on the screen 
until  after  the GP had made the decision to prescribe a benzodiazepine and (2) the 
risk indicator form had appeared on the screen irrespective of whether long-term use 
had (previously) been agreed upon with the patient.  
 
Effect of the risk indicator on the number of new long-term benzodiazepine users 
At the study practices, 108 out of the 2255 new benzodiazepine users had become 
long-term users before the intervention, compared to 102 out of the 2148  after the 
intervention(NS). At the reference practices, these figures were 62 out of 1674 versus 
66 out of 1666 (NS) (See table 1).  
 
Effect of the risk indicator on individual patients  
When we compared the group of patients in whom the risk indicator had been used 
over the total 3-year study period (n=366, see figure 4) to the group in whom it had 
not, we found an Odds Ratio of 1.48 (CI: 0.80-2.75) of becoming a long-term 
benzodiazepine user.  
 
Conclusions and Discussion 
Summary of the main findings 
To the best of our knowledge, this is  the first feasibility study on a risk indicator to 
prevent the long-term prescription of benzodiazepines on an  individual level in 
general practice. Our results indicated that an electronic risk indicator can be useful: 
the GPs reported that the risk score influenced their prescription  decision: the higher 
the risk score, the greater the influence. This resulted  in fewer prescriptions, 
abstaining from writing repeat prescriptions and stringent surveillance by means of 





prescriptions had been written  on medical grounds. This is an indication that the face 
validity of the risk indicator is valid.  
Incorporation of the risk indicator into the electronic patient record systems at the 
practices did not give rise to any technical problems. During the interviews most of 
the GPs confirmed that the risk score had provided positive support in their patient 
management. However, in two sets of circumstances, the current design had 
shortcomings: (1) the risk indicator had not  appeared on the screen until after the GP 
had made the decision to prescribe a benzodiazepine and (2) the risk indicator had 
appeared on the screen  irrespective of whether long-term benzodiazepine use had 
(previously) been agreed upon with the patient. This caused irritation and 
unnecessary extra work.  
There was no effect on the number of new long-term benzodiazepine users in the 
total study population, but when we focussed on the group in whom the indicator had 
been used  during the study period, a trend was found towards fewer new long-term 
benzodiazepine users (OR 1.48). However, the difference was not statistically 
significant. Therefore, it is premature to draw any definite conclusions about the value 
of the risk indicator in the prevention of new long-term BZ users. 
 
Comparison with the literature 
Although many authors have emphasised the need to reduce benzodiazepine use, 
the prevention of long-term use by means of individual  risk assessment has not been 
studied before to the best of our knowledge. 
Somewhat comparable was the study by Bonevski et al18.  on a computerised 
“continuing medical education”(CME) programme that screened for risk behaviours, 
including benzodiazepine use. It was concluded that the computer programme 
worked well. Nevertheless, the GPs reported that it was a major burden to complete 
the programme, because it increased the workload and was time-consuming. Some 
of the GPs in our study made comparable comments.  
 
Strengths and limitations of this study 
An explorative study design was chosen, because it was not clear what the impact of 
the intervention would be at the planning stage of this study.  One of the strengths 




was that insight was gained into the problems that GPs encounter with the risk 
supervision of long-term benzodiazepine users on a daily basis. 
Use of the most popular electronic patient record system and the recruitment of 
practices from a random sample, improved the external validity of the study. General 
practice electronic patient record systems were still under development  at the time of 
this study. Our findings are relevant to general practice presently and in the near 
future. The prospective design of this study and electronic data registration prevented 
recall bias.   
 
Limitations 
This study was conducted over a 3-year period, which had the advantage of 
providing a better view of the long-term effect of the intervention. We would have 
preferred a longer follow-up period, because the number of new long-term users in a 
year was low. 
 The main limitations of this study were that only moderate use was made  of the risk 
indicator and that a larger than expected number of practices (and thus patients) 
dropped-out  due to insufficient (computer) implementation options at the time of the 
study.  
 
Conclusion and implications for clinical practice and further research  
The core problem in long-term benzodiazepine use is the relief of symptoms that are 
mostly not just the result of medical problems, but also social or psychological 
problems30. Therefore,  it is important  to focus on the discontinuation of long-term 
benzodiazepine use and at the same time, make a positive contribution to solving the 
underlying medical and/or psychosocial problem(s).  There is a need for more 
treatment options in general practice, e.g. short cognitive behavioural training, or 
short problem-solving treatment for patients with these type of problem. Monitoring 
the individual risk of long-term benzodiazepine use is only (a small but relevant) part 
of it, but to be able to fulfil this role, the risk indicator has to become more user-
friendly. For example, it should only appear on the screen when a patient can be 
offered alternatives to benzodiazepine treatment and it must appear early in the 





In conclusion, further research has to be done in cooperation with GPs to improve 
interventions such as this risk indicator. Also, it is of great importance to search for 
solutions to  the problem of long-term benzodiazepine use in a completely different 
way, e.g. with input from other disciplines (politicians, social and auxiliary services). It 
is not just a problem for the GP, but requires a broader social approach. 
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Definition of the problem 
The theme of this thesis is derived from the application of benzodiazepines in health 
care, chiefly for the treatment of anxiety and sleeping problems, since their 
introduction in the nineteen sixties. In 2005, 1.25 million people in the Netherlands 
received a benzodiazepine primarily registered to treat anxiety disorders (anxiolytic), 
while 850,000 people received a benzodiazepine primarily aimed at sleep 
disturbances (hypnotic); a total of 12.2 million prescriptions crossed the counter at 
pharmacies1. The valid treatment principle is that short-term benzodiazepine use is 
very effective, whereas indications for long-term use are generally absent. However, 
in practice, it appears that more than 2%2 of the population (aged 18-75 years) 
receive long-term benzodiazepine prescriptions from their general practitioner (GP). 
Besides concerns about the lack of effectiveness in the long-term, particularly the 
side-effects have led to recommendations to exercise caution when writing 
prescriptions3, e.g. the risk of  addiction4-9, increased risk of (traffic) accidents10,11, in 
the elderly the risk of falling and sustaining femoral (and other bone) fractures12-16, 
cognitive disturbances17,18 such as antegrade amnesia19. Over the past 15 to 20 
years, various professional groups have developed and fine-tuned (multidisciplinary) 
guidelines3,20-25 that advocate the use benzodiazepines for a maximum of 2-12 
weeks, depending on the indication. 
 
This thesis arose from the need to stimulate rational prescription behaviour in general 
practice and accordingly aimed to reduce the number of long-term benzodiazepine 
prescriptions to patients. Broadly speaking, reduction can be achieved in two ways: 
curtailing existing long-term use and preventing new long-term use. 
The focus of this thesis was to develop an instrument that can help GPs to estimate 
the risk of long-term use before they write the first benzodiazepine prescription for 
their patient, in order to prevent long-term use. 
 
The study addressed the following questions: 
1  What are the consequences of different definitions of benzodiazepine use 
(duration of use and duration of the reference period) on prevalence rates? 
2  Are there differences in patient-related factors between short-term and long-term 
users in general practice? 
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3  Which psychological indications do GPs prescribe a benzodiazepine for and are 
these indications and prescription durations in conformity with the guidelines? 
4  Do patient-environmental factors, patient-related factors and GP-related factors 
influence the variation in long-term benzodiazepine prescription observed in 
general practice? 
5  How feasible is the use of a computerized “risk indicator questionnaire for long-
term benzodiazepine use” in terms of acceptance by GPs and its effect on the 
incidence of new long-term benzodiazepine prescriptions? 
 
Summary and findings 
The first half of the study formed part of the Regional Project Nijmegen II. Regional 
Project Nijmegen II is a continuation of Regional Project Nijmegen I that aimed to 
gain greater insight into “secular trends” in the occurrence of psychological 
disturbances. Regional Project Nijmegen II was performed in 1997 as an 
epidemiological study on the prevalence of psychological disturbances in the general 
population26. It comprised a prevalence study conducted by the Department of Social 
Sciences, Department of Psychiatry and the Department of General Practice of the 
UMC St Radboud. Information was obtained on, for example, the prevalence of 
psychiatric and psychosocial problems and their distribution over various groups in 
the population26-28. The section concerning benzodiazepines aimed to gain more 
insight into which patients run an increased risk of becoming long-term 
benzodiazepine users. For this purpose, patients who received long-term 
benzodiazepine prescriptions were compared to patients who received short-term 
benzodiazepine prescriptions (< 90 days). The data obtained from this comparison 
were used in the second half of this thesis to develop a risk indicator questionnaire to 
help GPs identify patients with an increased risk of becoming long-term users. In 
addition, attention was paid to psychiatric diagnoses and syndromes that may play a 
role, as well as to the psychological well-being and social functioning of the 
benzodiazepine users who participated in the study. 
 
Regional Project Nijmegen II had a cross-sectional research design, in which a 
random sample was drawn from the general population (≈ 82,350 patients from 32 





interviews, data were gathered in two phases to evaluate issues that included health 
status, social functioning and psychiatric morbidity.  In parallel, information was 
retrieved from the general practice information system on the use of psycho-
pharmaceuticals by all these patients to determine a.o. the representativeness of the 
random sample. In a separate phase, the GPs provided information about the 
interviewees after having received permission from each individual. 
 
Chapter 2 describes the effect of different definitions of benzodiazepine use and 
different reference periods on the prevalence rates of benzodiazepine use. 
In the literature, no uniform prevalence rates were available on benzodiazepine use. 
We analysed prescription data on psycho-pharmaceuticals over the period of 1 year 
at the 31 general practices and found that not only differences in the definition of 
benzodiazepine use alone, but also in combination with differences in reference 
periods, led to substantial deviation in prevalence rates. The influence of some 
benzodiazepine-user-related variables also become clear, such as age. 
 
What patient-related factors can be revealed by comparing long-term BZ users to 
short-term BZ users in general practice? (See also Chapters 3 and 4). 
From each general practice, random equal-sized samples were drawn of short-term 
and long-term receivers of BZ prescriptions. Their characteristics were compared in a 
multivariate logistic regression analysis. We found the following differences: long-
term users were more likely to be older, have a psychiatric history, have used 
psycho-pharmaceuticals in the past, have a lower feeling of well-being, be suffering 
from asthma, COPD, diabetes mellitus, hypertension and/or a severe skin disease for 
which they were receiving care from other medical specialists. In addition, more of 
the long-term users had a lower educational level, were suffering from loneliness and 
used avoidance coping strategies. An important finding was that there were no 
differences between the men and women. 
 
For which psychiatric indications does a GP prescribe a BZ and are these indications 
and the prescription durations in conformity with the guidelines? (Chapter 5) 
In the patients who had recently (within the past 90 days) received a BZ prescription 
from their GP, the correctness of this prescription was evaluated by comparing the 
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psychological problem recorded by the GP to the relevant GP guidelines on patient 
management and prescription duration criterion (<90 days). We found that 94 
patients had recently received a prescription for a BZ. In 33%, the indication was 
considered to be correct and in 4 patients, the prescription duration met the time 
criterion. 
 
What explains the differences in long-term BZ prescription behaviour between 
general practices? (Chapter 6) 
A 10-fold difference was found in the number of patients who were prescribed (long-
term) BZs between the general practices. Pearson correlations, univariate and 
multivariate multilevel analyses were used to identify factors to explain these 
differences. It was found that the following indicators were related to long-term BZ 
prescription: (1) GP-related: a) on the first prescription, more clearly defined daily 
dosage (DDD); b) many different types of BZ were prescribed; (2) patient-related: c) 
more commonly in women; d) at a more advanced age; (3) patient-environmental 
factors: e) socio-economic status (low income, unemployed, high address 
density/km2). A multilevel analysis model showed that the rates of explained variance 
in patient-related factors and practice-related factors were 93.8% and 6.2%, 
respectively. In the ultimate multilevel model, 28% of the variance was explained by 
all these indicators, divided into 4.6% practice-related factors and 23.4% patient-
related factors. 
 
The characteristics (“risk indicators”) identified in Chapters 3 and 4 were selected on 
the basis of their usefulness during a GP visit. General practices outside the regional 
project participated in the second part of this research. A panel of GP experts judged 
these risk indicators on the feasibility of their use in general practice consultations. 
This ultimately resulted in 6 questions, but “coping behaviour” and “loneliness” had to 
be excluded, because of the lack of uniformly applicable judgements and scores 
during consultation. On the basis of the final list of risk indicators, a computer 
programme was developed that produced a risk score. This programme was 
incorporated into the GP information system (HIS, see the Appendix), so that if 






Chapter 7 describes the feasibility study on the computerized risk indicator 
questionnaire in general practice. Attention was paid to the acceptance of the 
instrument by GPs and its effect on the frequency of new long-term BZ users in 
general practice. 
This descriptive quasi-experimental feasibility study was conducted at 30 general 
practices. We found that the risk indicator was used in +/- 25% of the new BZ 
prescriptions. When the GPs used the risk indicator, they stated that the score 
influenced the prescriptions in 22%. The higher the risk of long-term prescription, the 
greater the influence on the prescription behaviour of the GP (the difference was 
statistically significant). Limited consultation time and software problems hindered the 
otherwise positive experience with the instrument. Ultimately, it appeared that this 
intervention, in this form and under these circumstances, did not have any 
measurable effect on the number of new long-term BZ prescriptions. 
 
Summary conclusions 
In summary, we concluded that the prevalence rates reported in the literature could 
not be compared, owing to differences in the definitions of BZ use and the reference 
periods. In the literature, prevalences varied from 6.2%29 to 17.6%30, but it was 
striking that there was a lack of recent prevalence data. For long-term BZ use, 
prevalence figures varied from 0.5%31 to 5.8%30. In our study2, we found an annual 
prevalence of BZ use in the age group 18-75 years of 8.9%; (after correction for the 
Dutch age and gender distribution, the rate was 9.5%); about 2% were long-term BZ 
users. 
Within the framework of comparability between studies, we recommend the use of an 
annual prevalence, in which the definition of a long-term user is a person who uses 
BZs for more than 180 days per calendar year. 
The reason for this is that in an annual prevalence, figures can be generated of 
incidental BZ use and also long-term BZ use. If a person receives prescriptions for 
more than 180 days in one year, this is clearly beyond the advice of the guidelines. In 
the present era of computerization, it is also easy to generate an annual prevalence 
from the various data sets. At present, several countries have registries on BZ use, 
for example, in the Netherlands, pharmacies are keeping records of the BZ 
prescriptions they fill32 and there are also a number of GP registration networks e.g. 
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LINH33. The UK and Denmark also have large computerized registry data sets. To 
promote the comparison of data, close agreement on the definition of BZ use and 
reference period would provide greater insight into studies on the management and 
causes of differences in drug use and hopefully ultimately lead to better control of the 
problem. 
Our study on indications for BZ use (Chapter 5) showed that only 4% of the patients 
had received BZs for an appropriate indication and used them for <3 months. 
To gain more insight into the role of context factors in BZ use, we performed a study 
on the correlations between practice-related factors, patient-related factors and 
social-environmental-patient-related factors (Chapter 6). The results showed that the 
following factors were of importance: prescription behaviour of the GPs, the patient’s 
age (older) and gender (women). These factors together with a low socio-economic 
status influenced (increased) the risk of becoming a long-term BZ user. This 
combination of factors is in agreement with reports in the literature34-37. 
From our comparison between patients who received short-term prescriptions and 
patients who received long-term prescriptions, we derived a risk profile for the long-
term use of BZs and found that long-term users were more likely to be older, have a 
psychiatric history, have used psycho-pharmaceuticals in the past, be under the care 
of other medical specialists, be suffering from asthma, COPD, diabetes mellitus, 
hypertension and/or a severe skin disease and have a lower feeling of well-being. In 
addition, long-term users were more likely to have a low education level, be lonely 
and employ avoidance coping strategies. An important finding was that there were no 
differences in the risk of long-term use between men and women. Our findings 
agreed with those of Vissers36 who compared short: once only, short: episodic, long: 
episodic and long: continuously. Other studies in the literature did not make 
comparisons between short-term users and long-term users, they compared non 
users with BZ users. In the various studies (inclusive our study), the distributions of 
men and women who use BZ were 30-40% men and 60-70% women, therefore it is 
mentioned that women being more frequent users than men. However, our 
conclusion is that when a patient receives 1 prescription for BZs on one single 
occasion, the risk of long-term use is equal in men and women! 
The risk indicators identified in our study were judged on their feasibility for use in 





questions that were developed into a computer programme and incorporated into the 
GP information system. This software was implemented in the GP information system 
so that if necessary, the GP could determine a risk score during a consultation. The 
feasibility study in Chapter 7 showed that an increased risk score led to adjustments 
to the management policy. In addition, we found that the minimal intervention did not 
have any measurable effect on the number of new long-term users over a period of 
1.5 years. To our knowledge, no studies have focused specifically on the reduction of 
new long-term users, but the TPP study38 revealed that the largest effect was a 
reduction in the number of “new” BZ prescriptions. 
In the literature, there was wide variation in the results of studies on the 
implementation of assistance tools in general practice. Heideman39 conducted a 
systematic review on improving the management of anxiety disorders in general 
practice in 2005. It was concluded that combinations of professional and 
organisational interventions would have the most promising effect. 
 
Methodological considerations 
When we compared our results to those in the literature, it was striking that social 
factors were reported to play a role in long-term BZ use, but our comparison between 
short-term and long-term users did not confirm this. An explanation is that our 
working method may have excluded various social factors, because we consciously 
used matching to control for possible differences in practice factors and “drew” equal 
numbers of short-term and long-term BZ users from each general practice. This led 
to the present list of risk indicators that does not contain any social indicators. It 
should be remarked that the risk indicators identified by cross-sectional analysis were 
developed into an instrument and in a manner of speaking, put directly into practice. 
However, the risk factors found in our studies are not “absolute”. Therefore, it goes 
without saying that they need to be reconfirmed in an independent population40. 
Nevertheless, on the basis of the similarities with data reported in the literature and 
the logical reasoning behind the present risk indicators, in our opinion, the 
questionnaire can be used to estimate risk. 
It was striking that our study, on short-term users compared to long-term users, 
produced different results from those reported in the literature on non-users versus 
long-term users. As mentioned above, men and women were found to have an equal 
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risk of becoming long-term users at the time of receiving their first prescription for a 
benzodiazepine. However, more women were (long-term) users than men. These 
conclusions are the same as those in the study by Vissers36. Unfortunately, his thesis 
is written in the Dutch language, so the data are not easily accessible internationally. 
 
On the basis of all the studies together, we can draw the following conclusions: 
1.  Long-term benzodiazepine use is still a topical problem. 
2.  Long-term benzodiazepine use is a multifactorial problem that requires a 
multifactorial approach and is not the sole responsibility of the GP. 
3.  Risk indicator lists can make a contribution to prevention in general practice, but 
they need to be made more consultation-friendly and user-friendly and their 
implementation must occur in dialogue with the needs of the profession. 
 
Discussion 
Ad 1: Long-term benzodiazepine use is still a topical problem because: 
- the prevalence of long-term benzodiazepine use has not changed essentially 
over the past 40 years despite the development of guidelines for physicians and 
media attention to addiction. The results of the study on practice variations and 
the study on the indications for long-term benzodiazepine use showed that the 
attitudes of GPs play a role. In our feasibility study we found that GPs took action 
when the risk score was high, but the end result was that there was no 
measurable effect on the appearance of new long-term users. These results give 
possible indications of how persistent long-term benzodiazepine use is, which 
may be related to the second conclusion: 
 
Ad 2: Long-term benzodiazepine use is a multifactorial problem that requires a 
multifactorial approach. 
Besides the GP-related and patient-related factors, in practical terms particularly the 
more frequent occurrence of social problems in long-term users draws attention. 
It is too simplistic to ascribe long-term benzodiazepine use solely to the non-
evidence-based writing of prescriptions by GPs. This is also in conformity with the 





There is certainly still much to be achieved in general practice by means of 
prevention and measures to reduce benzodiazepine use. However, if health 
professionals want to approach the problem structurally, then more attention will 
need to be paid to the multilevel contributions of the different parties involved in this 
problem and the possible solutions to any further problems that arise. Insufficient light 
has been shed on the role of social problems that cannot be solved adequately within 
the context of medical health care. Stronger involvement of social-societal support 
might have a tangible effect on the use of benzodiazepines. In addition, it may need 
to be accepted that long-term benzodiazepine use is a “soothing agent” against many 
psychosocial insecurities and social inequalities. 
 
The question therefore arises: Are we being too paternalistic and judgemental? 
In his book entitled “Levenskunst op leeftijd” [The art of living at an advanced age: 
happiness-promoting care in an ageing world]49, Becker underlines the importance of 
the proper balance between Apolinistic (control, order, rule, regularity) and Dionysian 
(impulse, chaos, escape from rules) attitudes towards life. What then is the optimal 
balance between benzodiazepine use, indications for use, medically-evidence-based 
management, human happiness and benefit to life? Where does the doctor stand? 
This thesis cannot answer these questions, because the various studies had different 
focuses. However, we did encounter very different answers from the GPs who took 
part in the interviews in the feasibility study when we asked: What are your actual 
responsibilities as a GP? What can you do and what can’t you do? What do you want 
to achieve with your patients? 
 
Ad 3. Risk indicator lists can make a contribution to prevention in general practice, 
but they need to be made more consultation-friendly and user-friendly and their 
implementation must occur in dialogue with the needs of the profession. 
Our vision that monitoring prescription decisions can make a valuable contribution to 
reducing benzodiazepine use, was strengthened by our first experience with the 
newly developed risk indicator questionnaire and the responses we received from the 
GPs. An obvious prerequisite is that the tool is user-friendly and consultation-friendly 
(i.e. readily accessible in the electronic patient file). However, it is important to be 
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cautious in our expectations about the effect of a risk indicator questionnaire, in view 
of the other findings in this thesis. 
 
Recommendations for everyday practice: at present: 
In everyday practice, we recommend that benzodiazepine use and the associated 
side-effects are discussed with the patient in the light of the following list of targets in 
the ESCAPE acronym: 
Evidence-based reason to start prescribing a benzodiazepine 
Short-term prescription and set end-point 
Check effectiveness of benzodiazepine treatment 
Apply active weaning intervention  
Propose other treatment options 
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Dit proefschrift ontleent zijn thematiek aan de plaats die benzodiazepines sinds hun 
introductie in de 60-er jaren in de gezondheidszorg van de vorige eeuw innemen  bij 
het behandelen van voornamelijk angst en slaapproblemen. In Nederland kregen in 
2005 1,25 miljoen mensen een benzodiazepine primair geregistreerd als anxiolyticum 
en 850.000 een benzodiazepine primair geregistreerd als slaapmiddel. In totaal 
gingen 12,2 miljoen voorschriften bij de apotheek over de toonbank1. Als 
behandelingsprincipe geldt dat benzodiazepines voor kortdurend gebruik zeer 
effectief zijn, maar dat er voor langdurig gebruik nagenoeg geen 
behandelingsgronden zijn. In de praktijk blijkt echter meer dan 2%2 van de hele 
populatie (18-75 jarigen) chronisch benzodiazepines voorgeschreven te krijgen door 
de huisarts. Naast de twijfels over de effectiviteit op lange termijn zijn het vooral de 
bijwerkingen die tot een advies van terughoudend voorschrijven3 hebben geleid. En 
wel om de volgende redenen: de kans op het ontstaan van verslaving4-9, de 
toegenomen kans op (verkeers)ongevallen10,11 en, zeker bij ouderen, op vallen met 
daarbij o.a de kans op femurfracturen12-16  en  cognitieve stoornissen17,18 zoals 
antegrade amnesie . In de afgelopen 15 tot 20 jaar hebben de verschillende 
beroepsverenigingen gezamenlijk (multidisciplinaire) richtlijnen ontwikkeld en 
aangescherpt waarbij wordt geadviseerd om benzodiazepines afhankelijk van de 
indicatie maximaal 2-12 weken voor te schrijven3,19-24. 
Dit proefschrift komt voort uit de behoefte om rationeel voorschrijfgedrag in de 
huisartspraktijk te stimuleren.  Het richt zich daarbij op het terugdringen van het 
chronisch voorschrijven aan patiënten. De vermindering kan grofweg op twee 
manieren tot stand worden gebracht, namelijk het terugdringen van bestaand 
chronisch gebruik en het voorkomen van nieuw chronisch gebruik.  
De aandacht in dit proefschrift is gericht op het ontwerpen van een instrument dat 
huisartsen kan helpen  het risico op chronisch gebruik in te schatten voordat een 









Het onderzoek richtte zich daarbij op de volgende vragen:  
1 Wat zijn de consequenties van verschillen in definitie van benzodiazepine-
gebruik (tijdsduur van gebruik en tijdsduur van de referentieperiode) op de 
prevalentie-uitkomsten? 
2 Wat zijn patiënt-gerelateerde factoren van chronisch versus kort 
benzodiazepine-gebruik in de huisartspraktijk? 
3 Bij welke indicaties schrijft een huisarts een benzodiazepine voor en voldoet 
deze indicatie en de duur van het voorschrift aan richtlijnen? 
4 Wat is het aandeel van omgevingsfactoren, patiëntfactoren en 
huisartsfactoren, in de verschillende huisartspraktijken bij het chronisch 
voorschrijven van benzodiazepines. 
5 Hoe is de haalbaarheid van het gebruiken van een geautomatiseerde “risico-
indicator- vragenlijstje ter preventie van chronisch benzodiazepine-gebruik” in 
termen van acceptatie bij de huisarts? En hoe is het  effect van dit instrument 
op de incidentie van nieuwe chronische benzodiazepine-voorschriften?  
 
Samenvatting van de bevindingen 
Het eerste deel van het onderzoek is een deelonderzoek van het Regioproject 
Nijmegen II. Het Regioproject Nijmegen II is een vervolg op het Regioproject 
Nijmegen I om meer inzicht te krijgen over de “seculaire trends” in het voorkomen 
van psychische stoornissen. Het Regioproject Nijmegen II is een epidemiologisch 
onderzoek (1997) naar het voorkomen van psychische stoornissen in de open 
bevolking25. Het is een prevalentiestudie uitgevoerd door de afdelingen sociale 
geneeskunde, psychiatrie en huisartsgeneeskunde van het UMC St. Radboud. Het 
leverde onder andere informatie op over de prevalentie van psychiatrische en 
psychosociale problematiek en over de spreiding daarvan in diverse groepen25-27. 
Wat betreft het benzodiazepine-deel was de vraag  meer inzicht te krijgen in welke 
patiënten een verhoogd risico lopen om langdurig benzodiazepines te gaan 
gebruiken. Hiervoor zijn patiënten die langdurig benzodiazepines kregen 
voorgeschreven vergeleken met patiënten die kortdurend benzodiazepines kregen 
voorgeschreven (< 90 dagen). De gegevens die uit deze vergelijking zijn gekomen, 
zijn in het tweede deel van het onderzoek gebruikt voor de ontwikkeling van een 





risico hebben op het ontstaan van chronisch gebruik. Tevens is gekeken welke 
psychische diagnoses en syndromen hiermee samenhangen en hoe het psychische 
welbevinden en sociaal functioneren is van deze benzodiazepine-gebruikers. 
 
Het Regioproject Nijmegen II had een cross-sectioneel onderzoeksdesign waarbij er 
een steekproef werd genomen uit de open populatie (≈ 82.350 patiënten uit 32 
huisartspraktijken) in de regio Nijmegen. Met behulp van gestructureerde interviews 
werden in twee fasen gegevens verzameld ter bepaling van o.a. de 
gezondheidsstatus, het sociaal functioneren en de psychiatrische morbiditeit. Parallel 
hieraan werd van al deze patiënten uit de huisartsinformatiesystemen het 
psychofarmacagebruik verzameld voor de bepaling van o.a. de representativiteit van 
de steekproef.  Met toestemming van hun patiënten hebben de huisartsen bovendien 
informatie verstrekt over de geïnterviewde patiënten.  
 
In hoofdstuk 2 wordt beschreven wat het effect is van verschillende definities van 
benzodiazepinegebruik en verschillende onderzoeksperiodes op de prevalentie-
uitkomst van benzodiazepinegebruik. In de literatuur zijn geen eensluidende 
prevalentiecijfers te vinden met betrekking tot benzodiazepinegebruik. Wij 
analyseerden de prescriptiegegevens van psychofarmaca over de periode van 1 jaar 
van de 31 praktijken en stelden vast dat verschillende definities van 
benzodiazepinegebruik alleen als ook de combinatie van verschillende definities en 
verschillende referentietijdsperiodes tot wezenlijke verschillen in prevalentie leiden. 
Ook werd geïllustreerd wat daarbij de invloed van sommige benzodiazepinegebruik 
gerelateerde variabelen, zoals leeftijd, is.  
  
Welke voor patiënt gerelateerde indicatoren kunnen we vinden als we langdurige 
benzodiazepine-gebruikers vergelijken met kortdurende benzodiazepine-gebruikers 
in de huisartspraktijk.(zie ook hoofdstuk 3 en 4) 
Uit iedere huisartspraktijk werd een gelijk aantal patiënten at random geselecteerd 
die kort en chronisch benzodiazepinen kregen voorgeschreven. Hun gegevens 
werden vergeleken in een multivariate logistische regressie. Hieruit bleek het 
volgende: chronische gebruikers waren ouder, hadden vaker een psychiatrische 
voorgeschiedenis, gebruikten vaker psychofarmaca, hadden vaker astma, COPD, 




diabetes mellitus, hypertensie en/of een ernstige huidziekte waarvoor zij vaker onder 
behandeling van medische specialisten stonden, en zich minder gezond voelden. De 
chronische gebruikers waren ook vaak minder geschoold, eenzamer en maakten 
meer gebruik van vermijdend copinggedrag. Belangrijk feit is dat in het 
benzodiazepine gebruik geen rol speelde of het mannen of vrouwen betrof.  
 
Bij welke psychische indicaties schrijft een huisarts een benzodiazepine voor en 
voldoen deze indicatie en de duur van het voorschrift aan de richtlijnen? (hoofdstuk 5) 
Bij de patiënten die recent (afgelopen 90 dagen) een benzodiazepine door de huisarts 
voorgeschreven hadden gekregen, werd de juistheid van dit voorschrift onderzocht door 
de huisartsgeregistreerde psychoproblematiek te vergelijken met de hiervoor relevante 
richtlijnen voor huisartsgeneeskundig handelen en met het tijdsduurcriterium van 
voorschrijven (< 90 dagen). Er bleken 94 patiënten te zijn aan wie recent een 
benzodiazepine was voorgeschreven. Bij 33% was een terechte indicatie gesteld en bij 
4 patiënten werd er ook conform het tijdscriterium voorgeschreven. 
 
Wat verklaart de 10-voudig gemeten vastgestelde verschillen tussen 
huisartspraktijken in patiënten met langdurig voorgeschreven benzodiazepines? 
(hoofdstuk 6) 
Er bleek een 10-voudig verschil te bestaan tussen de huisartspraktijken in het aantal 
patiënten aan wie (chronisch) benzodiazepines waren voorgeschreven. Met behulp 
van Pearson-correlaties, univariate en multivariate multilevel technieken werd 
gezocht naar verklarende factoren voor deze verschillen. Hierbij bleek dat langdurig 
voorschrijven was gerelateerd aan de volgende indicatoren: (1) huisarts-
gerelateerd:a) bij het eerste voorschrift meer gedefinieerde dagdoseringen (DDD), 
gemiddeld werd er voor 11 DDD (spreiding 5-22) voorgeschreven b) veel soorten 
benzodiazepines voorschrijven (gemiddeld 10, spreiding 4-18) ; (2) patiënt 
gerelateerd:c) vaker bij vrouwen; en d) bij een hogere leeftijd; (3) omgevingsfactoren: 
(e) sociaaleconomische status (laag inkomen, niet werkend, hoge 
adressendichtheid/km2). In een multilevel-analyse-model bleek de onderlinge 
verdeling tussen de verklarende factoren respectievelijk, 93,8% patiëntfactor en 6,2% 
praktijkfactor. In het uiteindelijke multilevel model werd met al deze indicatoren 28% 





De in hoofdstuk 3 en 4 gevonden kenmerken (‘risico-indicatoren’) werden 
geselecteerd op hun bruikbaarheid tijdens een huisartsconsult. Dit tweede deel van 
het onderzoek werd gedaan in praktijken buiten het regioproject. Een panel van 
huisartsdeskundigen beoordeelde deze risico-indicatoren op hun bruikbaarheid in de 
consultvoering in de huisartspraktijk. Dit resulteerde uiteindelijk in 6 vragen, waarbij 
bijvoorbeeld ‘coping gedrag’ en ‘eenzaamheid’ afvielen gezien het ontbreken van een 
eenduidig toepasbare beoordeling en score tijdens de consultvoering. Op basis van 
de lijst met uiteindelijk gekozen risico-indicatoren werd een software programma 
gemaakt dat de risicoscore bepaalde. Dit software programma werd ingebouwd in 
het geautomatiseerde huisartsen informatiesysteem (HIS, zie bijlage), zodat tijdens 
het spreekuur de huisarts indien noodzakelijk een risicoscore kon bepalen.  
 
Hoofdstuk 7 beschrijft vervolgens de haalbaarheidsstudie van de geautomatiseerde 
risico-indicator vragenlijst in de huisartspraktijk. Hierbij werd gekeken naar de 
acceptatie van huisartsen van dit instrument en het effect op de frequentie van 
nieuwe chronisch benzodiazepinegebruikers in de huisartspraktijk.  
Deze beschrijvende quasi experimentele haalbaarheidsstudie werd uitgevoerd bij 30 
huisartspraktijken. Het bleek dat de risico-indicator bij +/- 25% van de nieuwe 
benzodiazepine-voorschriften was gebruikt. Als de huisarts de risico-indicator 
gebruikte, had de score volgens opgave van de huisartsen in 22% invloed op het 
voorschrijven. Hoe hoger het risico op chronisch voorschrijven, hoe meer dit van 
invloed was op het voorschrijfgedrag van de huisarts (dit was een significant 
verschil). De consulttijd en softwareproblemen bemoeilijkten  aan de andere kant de 
positieve ervaringen. Uiteindelijk bleek dat deze interventie in deze vorm en onder 
deze omstandigheden uitgevoerd, geen meetbaar effect had op het aantal nieuwe 
chronische benzodiazepine voorschriften. 
 
Samenvatting conclusies  
Samenvattend hebben we geconcludeerd dat de verschillende prevalentiemetingen 
onderling niet vergelijkbaar zijn door de wisselende definities van benzodiazepine 
gebruik en de periode waarin dit werd gemeten. In de literatuur werden prevalenties 
genoemd variërend van 6,2 28 t/m 17,6 29 waarbij tevens opvalt dat er weinig recente 
prevalentiecijfers bekend zijn. Voor chronisch benzodiazepinegebruik variëren de 




prevalentie cijfers van 0,530 t/m 5,829. In onze studie2 hebben we een jaarprevalentie 
van benzodiazepinegebruik in de groep van 18-75 jarigen gevonden van 8,9% 
(gecorrigeerd voor de Nederlandse leeftijd en geslachtsverdeling is deze 9,5 %). 
Chronisch gebruik komt voor bij ongeveer 2 % van de hele onderzochte populatie.  
 
In het kader van onderling vergelijkbare studies is onze aanbeveling om te spreken 
van een jaarprevalentie waarbij als definitie van een chronisch gebruiker wordt 
gehanteerd dat iemand meer dan 180 dagen per kalenderjaar benzodiazepines 
gebruikt .  
 
Reden voor de keuze van een jaarprevalentie is dat je dan zowel cijfers kan 
genereren van incidenteel benzodiazepine gebruik als ook van langdurig 
benzodiazepine gebruik. Indien iemand meer dan 180 dagen in een jaar een 
voorschrift krijgt is er duidelijk sprake van langer dan volgens de richtlijnen gewenst 
gebruik. In het huidige automatiseringstijdperk is een jaar prevalentie ook makkelijker 
te achterhalen uit de verschillende datasets. Momenteel zijn er in diverse landen 
duidelijke registraties van gebruik. In Nederland bijvoorbeeld registreren de 
apotheken hun uitgiftes van benzodiazepinerecepten31. Daarnaast zijn er ook nog 
een aantal netwerken van huisartsen praktijken waarvan geanonimiseerd gegevens 
in een centrale database worden geregistreerd bijvoorbeeld LINH32. Ook in Engeland 
en in Denemarken zijn grote geautomatiseerde registratiebestanden. Voor de 
onderlinge vergelijkbaarheid zou een betere afstemming van definitie van het gebruik 
het wederzijds onderzoek naar aanpak en oorzaken van verschillen in 
medicatiegebruik meer inzicht kunnen geven en hopelijk zo tot uiteindelijk een betere 
aanpak van het probleem kunnen leiden.  
Uit ons onderzoek naar indicatieredenen voor gebruik (hoofdstuk 5) bleek dat maar 4 
% van de patiënten op een terechte indicatie < 3 maanden benzodiazepines gebruikt.  
Om meer inzicht te krijgen in het aandeel van de contextfactoren van benzodiazepine 
gebruik hebben we onderzoek gedaan naar de onderlinge samenhang tussen 
praktijkfactoren, patiëntfactoren en  sociale omgevingsfactoren van de patiënt 
(hoofdstuk 6). Uit dit onderzoek bleek dat het voorschrijfgedrag van de huisarts, 
leeftijd van de patiënt (hogere leeftijd) en geslacht (vrouwen) van belang zijn en 





(namelijk meer kans) om chronisch benzodiazepines te gaan gebruiken. De 
combinatie van factoren die we hebben gevonden komt overeen met wat beschreven 
wordt in de literatuur33-36. 
Naar aanleiding van onze vergelijking van patiënten die kort en langdurig 
benzodiazepinen kregen voorgeschreven hebben we als risicoprofiel van de 
“”chronisch voorschrift-gebruikers” gevonden dat ze ouder waren, vaker een 
psychiatrische voorgeschiedenis hadden, meer psychofarmaca hadden gebruikt in 
het verleden, vaker onder behandeling waren van andere medische specialisten, 
vaker astma, COPD, diabetes mellitus, hypertensie en/of een ernstige huidziekte 
hadden en zich minder gezond voelden. Daarbij waren de chronische gebruikers ook 
vaak minder geschoold, eenzamer en ze maakten meer gebruik van vermijdend 
coping gedrag. Belangrijk feit is dat er GEEN geslachtsverschil werd gevonden in het 
risico op chronisch gebruik. Onze bevindingen komen overeen met de studie van 
Vissers36 die kort eenmalig, kort-episodisch, lang- episodisch en lang-continu 
vergeleek. De overige literatuurgegevens vergelijken niet-gebruikers met langdurige 
gebruikers, waarbij blijkt dat er meer vrouwen dan mannen benzodiazepines 
gebruiken. Deze bevinding komt overeen met onze en Vissers’ bevindingen als we in 
onze populaties de niet-gebruikers met chronische gebruikers vergelijken. Over de 
diverse onderzoeken variëren de man – vrouw-verhoudingen respectievelijk van 30-
40% mannen en 60-70% vrouwen. Onze conclusie is echter dat het risico op 
chronisch gebruik voor mannen en vrouwen gelijk is bij mensen die eenmaal een 
recept voor benzodiazepines hebben gekregen!  
De gevonden risico-indicatoren hebben we op hun bruikbaarheid in de 
consultvoering in de huisartspraktijk laten beoordelen door een panel van 
huisartsdeskundigen. Dit resulteerde in 6 vragen, waar een software programma mee 
is gemaakt (zie bijlage). Deze software werd geïmplementeerd in het HIS zodat 
tijdens het spreekuur de huisarts indien noodzakelijk een risicoscore kon bepalen. In 
de in hoofdstuk 7 beschreven haalbaarheidstudie bleek dat bij een verhoogd 
risicoscore huisartsen hun beleid aanpasten. Tevens bleek dat de minimale 
interventie bij het aantal nieuwe chronische gebruikers na 1,5 jaar gebruik geen 
meetbaar resultaat had. Betreffende het terugdringen van nieuw chronisch gebruik 
zijn geen eerdere specifieke studies bekend. Wel werd in de TPP-studie37 als 




grootste effect gevonden dat er minder “nieuwe” benzodiazepinevoorschriften 
werden uitgeschreven.  
In de literatuur worden er sterk wisselende resultaten beschreven over 
implementaties van hulpinstrumenten voor de huisartspraktijk. In een systematische 
review van Heideman38, betreffende verbetering van het management van 
angststoornissen in de huisartspraktijk in 2005, concludeerde men dat combinaties 
van professioneel en organisatorische interventies het meest veelbelovende effect 
zouden hebben.  
 
Methodologische opmerkingen 
In de literatuur valt op dat sociale factoren een rol spelen bij chronisch gebruik. In 
onze vergelijking van kortgebruikers met langgebruikers werd dit niet gevonden. 
Onze verklaring hiervoor is dat onze werkwijze, waarin bewust de praktijkfactoren 
werden weggematcht door gelijke aantallen korte en chronische gebruikers uit de 
verschillende praktijken te “trekken”, mogelijk een deel van de sociale factoren  deed 
wegmatchen. Onze werkwijze heeft aldus geresulteerd in de huidige risico-
indicatorenlijst zonder sociale indicatoren. Tevens moet hierbij worden opgemerkt dat 
de uit cross-sectioneel gevonden risico-indicatoren zijn ingebouwd in een instrument 
en zo bij wijze van spreken rechtstreeks doorgevoerd zijn naar de praktijk. Echter de 
gevonden risico-indicatoren zijn niet “absoluut”. Daarom is het zonder meer 
noodzakelijk om de hier gevonden indicatoren nog eens te bevestigen in een 
onafhankelijke populatie39.  
Ondanks de hiervoor genoemde noodzaak van bevestiging en de mogelijk gemiste 
extra risico-indicator vinden we, dat, op basis van de uit de literatuurgegevens en de 
logische beredeneerbaarheid van de gevonden huidige risico-indicatoren, we wel 
een mogelijk verhoogde kans op chronisch gebruik van benzodiazepines kunnen 
bepalen.  
Opvallend is wel dat ons onderzoek waarin patiënten worden vergeleken die 
kortdurend een benzodiazepine kregen voorgeschreven met patiënten die chronisch 
benzodiazepine kregen voorgeschreven andere uitkomsten geeft dan de in de 
meeste literatuur gemaakte vergelijking van geen-gebruikers versus chronische 
gebruikers. Zoals al genoemd is het meest opmerkelijke feit dat het risico om een 





eenmaal een benzodiazepine krijgen voorgeschreven. Er zijn wel meer vrouwen die 
(chronisch) benzodiazepine gebruiken in vergelijking met mannen. Deze conclusies 
zijn dezelfde als die Vissers36 in zijn onderzoek heeft gevonden. Helaas is Vissers’ 
proefschrift alleen in het Nederlands geschreven waardoor zijn gegevens 
internationaal niet goed toegankelijk zijn. 
 
Uit al deze studies bij elkaar trekken we de volgende conclusies: 
1. Chronisch benzodiazepinegebruik is nog steeds een actueel probleem.  
2. Chronisch benzodiazepinegebruik is een multifactorieel probleem en verdient 
een multifactoriële aanpak en valt dus niet alleen onder de verantwoordelijkheid 
van de huisarts. 
3. Gebruik van de risico-indicatorenlijst kan een preventieve bijdrage hebben in de 
huisartspraktijk mits de lijst gebruiksvriendelijker wordt gemaakt en in 
samenspraak met de beroepsgroep wordt geïmplementeerd. 
 
Discussie 
Ad 1:Chronisch benzodiazepinegebruik is nog steeds een actueel probleem . 
De prevalentie van chronisch benzodiazepinegebruik is in de afgelopen 40 jaar niet 
essentieel veranderd ondanks ontwikkeling  van richtlijnen voor artsen en aandacht 
in de media voor het risico van verslaving. De uitkomst van zowel de studie naar 
praktijkvariatie alsook die van  de studie naar  indicaties voor langdurig gebruik laten 
zien dat de houding van de huisarts van essentieel belang is. Het resultaat van de 
haalbaarheidsstudie laat zien dat als huisartsen “wel handelen” bij een hoge 
risicoscore (dus aangeven dat ze duidelijk stilstaan bij de waarschuwing door en/of 
minder tabletten en/of anderszins aanvullende maatregelen nemen ter preventie van 
chronisch gebruik) er tenslotte geen meetbaar effect is op de nieuw ontstane 
chronische gebruikers. Dat geeft aan hoe hardnekkig chronisch benzodiazepine-
gebruik is. Een en ander hangt naar alle waarschijnlijkheid samen met de tweede 
conclusie.  
 




Ad 2: Chronisch gebruik is een multifactorieel probleem en verdient een 
multifactoriële aanpak. 
Naast de huisarts- en patiëntfactoren in de praktijk speelt in het bijzonder het meer 
voorkomen van sociale problemen bij langdurige gebruikers ten op zichtte van 
kortgebruikers.  
Chronisch benzodiazepinegebruik is dus niet alleen toe te rekenen aan het 
voorschrijfgedrag van huisartsen. Deze conclusie past ook bij de in de literatuur 
gevonden wisselende resultaten van interventies40-47. Er is zeker nog winst te 
behalen in de huisartspraktijk door middel van preventie en aanpak van reductie van 
benzodiazepinegebruik. Maar wil men structureel wat doen aan het probleem dan zal 
er op meer fronten gekeken moeten worden naar de bijdrages van de verschillende 
partijen en naar mogelijke oplossingen.  Onderbelicht lijkt daarbij de rol van de 
sociale problemen die niet goed via de medische zorg zijn op te lossen. Een sterkere 
betrokkenheid van sociaal-maatschappelijke zijde zou mogelijk een positief effect  
kunnen hebben. Daarnaast moet misschien ook worden geaccepteerd dat chronisch 
benzodiazepinegebruik een verzachtend middel is voor patiënten met problemen op 
psychosociaal en/of maatschappelijk gebied.  
De vraag die daarbij tevens opkomt is “zijn we te betuttelend bezig?”. Becker schrijft 
in zijn boek “Levenskunst op leeftijd”48 over het belang van het combineren van 
“Apollinische”(maat houden en rede) en  Dionysische (ontsnappen aan regels en vrij 
spel geven aan emoties) aspecten van het leven. Wat zou nu de optimale balans zijn 
tussen benzodiazepinegebruik, indicaties voor gebruik, het medisch verantwoord 
handelen en menselijk geluk en levenswinst. Waar hoort de dokter hierin te staan? 
Dit proefschrift kan hier geen uitspraken over doen omdat het onderzoek in de 
verschillende studies hier niet op gericht was. Wel kan gezegd worden dat uit de 
interviews met de huisartsen, die aan de haalbaarheidsstudie deelnamen, duidelijk 
verschillende vragen kwamen over waar ben je als huisarts nu wel verantwoordelijk 







Ad 3:  Preventie van chronisch benzodiazepine gebruik met de risico-indicatorenlijst 
kan zijn bijdrage hebben in de huisartspraktijk mits het consult- en gebruikersvrien-
delijker wordt gemaakt en in samenspraak met de behoeftes van de beroepsgroep 
wordt geïmplementeerd. 
De eerste ervaringen met de in dit onderzoek ontwikkelde risico-
indicatorenvragenlijst en de respons die daarover van huisartsen kwam, sterkt ons in 
de visie dat monitoren van voorschrijfbeslissingen een zinvolle bijdrage kan leveren 
aan het terugdringen van benzodiazepinegebruik. Voorwaarde is wel een 
gebruiksvriendelijke inpassing in het elektronische dossier en in de consultatie. 
Daarbij moet dan wel worden gewaakt voor te grote verwachtingen van het effect, 
gezien de andere hier gerapporteerde bevindingen.  
 
Aanbevelingen voor de praktijk op dit moment. 
Voor de dagelijkse praktijk wordt geadviseerd om benzodiazepinegebruik en de 
daaraan verbonden nadelige effecten met de patiënt te bespreken aan de hand van 
de volgende doelstellingen. In het Engels de ESCAPE-acronym: 
Evidence based reason to start prescribing a benzodiazepine 
Short-term prescription and set-end-point 
Check effectiveness of benzodiazepine treatment 
Apply active weaning intervention  
Propose other treatment options 
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Benzodiazepine Risk Indicator for Chronic Use (BenRICU) 
 
Hoe is de BenRICU ontstaan? 
Chronisch benzodiazepine gebruik in de huisartspraktijk is vaak een ongewenst 
resultaat van ooit voorgeschreven benzodiazepinen. Het stoppen van chronisch 
benzodiazepine gebruik is geen makkelijke taak. Het is zaak te voorkómen dat 
benzodiazepine gebruik chronisch wordt. Indien er een indicatie is voor 
kortdurend benzodiazepine gebruik, zoals bijvoorbeeld bij angststoornissen,  dan 
is het belangrijk om vanaf het begin afspraken te maken met uw patiënt over de 
duur van het gebruik van deze geneesmiddelen, met name bij patiënten die nog 
meer risico lopen op chronisch gebruik dan anderen. Om dit risico in te schatten 
is de BenRICU ontwikkeld. 
De BenRICU is ontwikkeld na analyse van de gegevens die in samenwerking 
met het Regio-project II zijn verzameld. Voor het Regio-project II zijn in 33 
huisartspraktijken gegevens verzameld over psychopathologie, de behandeling 
hiervan en de kenmerken van de patiënt. Uit deze databank is een selectie 
gemaakt van chronische en kortdurende benzodiazepine gebruikers.  Deze twee 
groepen zijn vervolgens vergeleken op hun afzonderlijke kenmerken. Na analyse 
van deze gegevens bleven er 8 kenmerken over die chronisch benzodiazepine 
gebruikers van kortdurende gebruikers onderscheiden. Hieruit zijn 6 kenmerken 
die voor een huisarts eenvoudig te beoordelen zijn geselecteerd. Deze 6 
kenmerken worden gevraagd in de BenRICU.  
  
Wat is de BenRICU? 
De BenRICU is een vragenlijst bestaande uit 6 vragen. De antwoorden op deze 
vragen zijn de huisarts bekend of staan ergens geregistreerd in het Huisarts 
Informatie Systeem. Het zijn vragen naar risicofactoren voor het ontstaan van 
chronisch benzodiazepine gebruik. Per vraag is de bijdrage aan het totale risico 
uitgedrukt in een eigen odds ratio. Met behulp van een rekenprogramma kan 
voor ieder individu zijn of haar afzonderlijke kans op chronisch benzodiazepine 
gebruik worden bepaald. 
Met de BenRICU berekent u dus een PERCENTAGE KANS OM CHRONISCH 
BENZODIAZEPINE GEBRUIKER te worden. 
 
Wanneer is het belangrijk om de BenRICU te gebruiken? 
Indien u als huisarts overweegt om voor de eerste keer een benzodiazepine voor 
te schrijven aan een patiënt is het van belang als u vooraf deze signaleringslijst 
invult. U kunt hiermee een betere risico inschatting maken, zodat u vooraf uw 
beleid hierop kan afstemmen. 








Hoe moet de BenRICU gebruikt worden? 
Na de installatie is het PNS Benzo programma op te starten vanaf de icoon in de 
PNS-groep. 
U moet het programma zelf opstarten nadat u MicroHIS gestart bent, vergeet dit 
niet! Anders staat de waarschuwingsmodule niet aan. Als u het programma 
opstart voordat u met MicroHIS begonnen bent, dan komt er een melding.  
De volgorde is dus: 
1. Start MicroHIS 
2. Start PNS Benzo project 
Het PNS programma komt automatisch op de voorgrond indien er een 
benzodiazepine recept wordt voorgeschreven. In beeld komt dan de melding of u 
gedacht heeft aan de BenRICU. 
Als u hier “ja” aanklikt dan verschijnt de BenRICU op het scherm. Een enkele 
keer kan het zo zijn dat dit niet gebeurt omdat een MicroHIS-melding de 
BenRICU-melding “wegdrukt”. U kunt dan handmatig naar het PNS-
programma  met <Alt-Tab> of door in Windows 95/98 in de taakbalk de knop 
<PNS-Benzo-project> aan te klikken. Onder <Akties> kiezen voor de 
<geselecteerde patiënt> en vervolgens de BenRICU in te vullen. 
 
Alle vragen welke bij het programma horen staan in één scherm, u beantwoordt 
alle vragen achtereenvolgens. Het invullen van de BenRICU hoeft u niet meer 
dan 1 minuut tijd te kosten. U kunt als u de antwoorden op de vragen niet weet, 
de vraag aan de patiënt stellen of eventueel onbekend invullen. De Tussendoor 
kunt u met de optie <naar MicroHIS> even in de gegevens van de patiënt kijken 
en dan weer terug met <Alt-Tab> of via de taakbalk. Vult u “onbekend” in dan 
gaat de BenRICU bij het berekenen van de kans uit alsof er bij die vraag “Nee” 
is ingevuld. (het risico om benzodiazepine gebruiker te worden wordt dus 
onderschat als u veel vragen invult als onbekend) 
 
Met de drukknop <Gereed> slaat u de gegevens van de BenRICU op. Als u ze 
toch nog wilt verbeteren kan dit door op <Opnieuw> te klikken. U kunt hiermee 
alleen de laatst ingevulde BenRICU verbeteren. De andere BenRICU‟s kunt u 
dus niet meer veranderen. 
 
Met drukknop <Einde> wordt het programma afgesloten zonder de laatst 
ingevulde gegevens te verwerken. U zet hiermee het PNS programma uit! 
 
Let op: in een enkel geval kan het gebeuren dat een MicroHIS-melding de 
Benricu-melding op uw scherm „wegdrukt‟. U moet er dan zelf aan denken om  
alsnog de Benricu gegevens in te voeren. U gaat dan handmatig naar het PNS 
programma met <Alt-Tab> of door in Windows 95/98 in de taakbalk de knop 





Toelichting bij de items van de BenRICU? 
 
Hieronder komt per vraag het scherm wat u ziet en de eventuele 




Heeft uw patiënt een van de 
volgende chronische ziektes te 
weten; diabetes mellitus, 
hypertensie, astma/ COPD, en/of 
een ernstige huidziekte?   
Invul opties: Nee / Ja / Onbekend   Odds ratio = 1,7 
 
Indien het programma een probleem of episode vindt welke aan de criteria 
voldoet, dan wordt keuzerondje "Ja" reeds ingevuld. Het programma kan 
uitsluitend op ICPC-code zoeken. Met de drukknop <Toon> kunt u de gegevens 
van uw patiënt z‟n probleemlijst inzien. Hiermee kunt u deze vraag hopelijk snel 
beantwoorden. 
Een ernstige huidziekte is een huidziekte waar uw patiënt subjectief veel 
klachten en hinder van ondervindt. Het kan een psoriasis of ernstig eczeem zijn. 
Maar niet alle patiënten met psoriasis of eczeem hebben er erg veel last van. 
Sommige hebben maar 2 kleine plekjes en meer niet. Dan is dit geen ernstige 
huidziekte. Heeft uw patiënt er wel veel last van dan is het wel een ernstige 




Is uw patiënt in het afgelopen 
jaar onder behandeling geweest 
van een medisch specialist, met 
uitzondering van de oogarts?  
Invulopties: Nee / Ja / Onbekend   Odds Ratio= 1,6 
 
Vraag 3 
Heeft uw patiënt in het afgelopen 
jaar psychofarmaca gebruikt? 
Zoals antidepressiva, anti-
psychotica, en / of tranquillizers 
(slaap- en of kalmerings-
middelen)? 
 









Indien het programma een recept in het afgelopen jaar van één van deze 
psychofarmaca vindt die aan de criteria voldoet, dan wordt keuzerondje "Ja" 
reeds ingevuld. Met drukknop <Toon> ziet u de medicatievoorschriften van het 
afgelopen jaar. Klikt u op psychofarmaca dan ziet u alleen de psychofarmac van 
dit jaar. Zo kunt u de gegevens dus snel controleren. 
Als uw patiënt in het afgelopen jaar alleen bijvoorbeeld 2 temazepam tabletjes 
voor de vliegreis heeft gehad, wordt de vraag van psychofarmaca gebruik in het 
afgelopen jaar met nee beantwoord. Bij alle andere indicaties en psychofarmaca 
gebruik beantwoordt u deze vraag met ja. 
 
Vraag 4 
a) Is uw patiënt ooit (afgelopen 
5-10 jaar) behandeld door 
een psychiater of 
opgenomen geweest voor 
psychiatrische behandeling? 
b) Of is uw patiënt ooit 
behandeld voor problemen 
vanwege teveel alcohol 
gebruik? 
 
Invulopties: Nee / Ja / Onbekend 
 
Ad a  De tijdslimiet is niet zo exact, de vraag is of uw patiënt bekend is met dit 
soort problemen in de voorgeschiedenis. Er wordt hier niet bedoeld een 
behandeling door het maatschappelijk werk of door een psycholoog. Als u het 
niet weet en vermoedt dat uw patiënt wel een psychiatrische voorgeschiedenis 
heeft kunt u het uw patiënt ook altijd nog vragen. 
Ad b  Hiermee wordt bedoeld dat u of bijvoorbeeld het CAD uw patiënt 
behandeld heeft voor problemen met alcoholgebruik. De tijdslimiet is wederom 




Is uw patiënt ouder dan 50 
jaar? Dit wordt door de 
computer berekend en 
ingevuld. 
 










Heeft uw patiënt voor z'n 






Invulopties: Nee / Ja / Onbekend    Odds Ratio= 9,4 
 
Dit is u meestal wel bekend en eventueel kunt u het u patiënt ook altijd vragen. 
Deze vraag is vooral van belang bij het voorschrijven aan jongere patiënten (< 
30 jaar).    
 
In het kader van het onderzoek naar de invloed van de BenRICU op voorkómen 
van nieuwe chronische benzodiazepine gebruikers, is het belangrijk om te weten 
of deze risico inschatting ook van belang is voor uw beleid. Hiervoor is de extra 
vraag toegevoegd of deze score uw beleid beïnvloedt. 
 
Indien "Nee", dan zijn er 5 antwoord opties, zoals hieronder vermeld. 
 
Als indicaties worden hier 
bedoeld diegene die in de 
NHG-standaard staan 
vermeld; te weten kortdu-
rende angst en/of paniek-
stoornissen; kortdurende 
slaapproblemen. 
Bij de optie "Anders" kunt u met maximaal 60 tekens een korte opmerking 
plaatsen waarom u uw beleid niet heeft veranderd, desnoods kunt u naar het 
journaal verwijzen. 
 
Indien "Ja", dan zijn er 8 mogelijkheden vooraf genoemd hoe uw beleid 
gewijzigd zou kunnen zijn. 
 
Ook hier is bij de optie 
"Anders" een opmerkings-












Op het einde moet u met drukknop <Gereed> de gegevens wegschrijven naar de 
harde schijf. Hiervoor is het noodzakelijk dat u alle gegevens ingevuld heeft, 
anders komt er een melding. 
Met drukknop <Opnieuw> kunt u de laatst weggeschreven gegevens opnieuw 
ophalen en verwerken, wellicht omdat u de eerste maal een fout gemaakt had. 
Dit kunt u doen zolang u in MicroHIS nog geen nieuwe patiënt geselecteerd 
heeft. 
 
Let op: met de drukknop <Einde> wordt het programma afgesloten zonder 
de laatst ingevulde gegevens te verwerken. U zet hiermee het PNS 
programma uit! U krijgt dan dus ook geen BenRICU waarschuwing meer. 
 
Besluit u  om  geen benzodiazepines voor te schrijven, dan is het belangrijk 
voor de registratie van het onderzoek, dat u het recept wat u heeft 
uitgeschreven weer laat vervallen. U doet dit als volgt: U heeft de BenRICU 
ingevuld en komt dan met <naar MicroHIS> weer in het voorschriften scherm 
van MicroHIS. U klikt dan het reeds voorgeschreven recept aan zodat u het 
voorschrift kan wijzigen of laten vervallen. Laat u het vervallen dan klikt u 
<vervallen> aan en vervolgens klikt u <verwerk> aan. De computer vraagt dan 
wilt u dit recept laten vervallen? Waarop u <ja> aanklikt. Voor wijzigen werkt 




Wat zijn alternatieven voor behandeling: 
Geen benzodiazepine, maar afhankelijk van de indicatie bijvoorbeeld een 
slaapcursus of ontspanningsoefeningen bij de fysiotherapeut of haptonoom. 
 In plaats van een benzodiazepine een Selectieve Serotonine Re-uptake 
Inhibitor. 
 Of misschien is hier een indicatie voor een ander antidepressivum. 
 
Als u besluit om een benzodiazepine voor te schrijven volgen hier onder enkele 
adviezen ten aanzien van de begeleiding van het gebruik. 
* Om te ervoor te zorgen dat uw nieuwe benzodiazepine gebruiker niet 
gemakkelijk herhaalrecepten kan krijgen, kunt u  uw assistente hierop 
attenderen, door bij het recept uit schrijven de optie van niet herhalen aan te 
kruisen. Uw assistente ziet dit dan bij de aanvraag van het herhaalrecept en kan 
afhankelijk wat u met haar afspreekt het herhaalrecept niet verstrekken. Of de 
patiënt  een afspraak op het spreekuur laten maken. 
* Ook kunt u meteen bij het voorschrijven een vervolg afspraak laten maken 
voor verdere begeleiding. 
* Of bij het voorschrijven van het eerste recept meteen met uw patiënt afspraken  





 Gegevens verzamelen en versturen (uitspoelen)   
 
Tijdens en na afloop van het project kan u worden gevraagd om de reeds 
geregistreerde gegevens uit te spoelen (het logbestand wordt dan naar een 
diskette gekopieerd). U doet dit als volgt. In het PNS programma staat links 
boven aan <Bestand>. Dit klikt u aan. Hier onder verschijnt de mogelijkheid  
<Bestand-Naar diskette>. U geeft dan de naam van het diskettestation op 
(meestal a). En drukt op <enter>, waarna het bestand wordt weggeschreven op 
de diskette in het station a. 
 
De eerste keer is het belangrijk dat u test of alles goed geïnstalleerd is hiervoor 
staat hieronder de gegevens van een door u in te vullen proefpatiënt. En op 
diskette 2 een “uitspoel” te maken en naar ons terug te sturen in de diskette 
envelop. 
 
1 PROEF INVUL PATIENT BenRICU 
Kies uw eigen “dummy”patiënt (hopelijk is deze meer dan 50 jaar oud). 
 
Vul bij deze patiënt de volgende antwoorden in: 
Vraag 1: Bekend met DM of hypertensie of COPD of ernstige  
huidziekte            JA 
Vraag 2: Onder behandeling geweest van een specialist het  
afgelopen jaar?         NEE 
Vraag 3: In het afgelopen jaar psychofarmaca gebruikt?   NEE 
Vraag 4: Ooit behandeld door een psychiater of voor  
problematisch alcohol gebruik?      NEE 
Vraag 5: Leeftijd boven de 50 jaar?    
(automatisch ingevuld)        JA 
Vraag 6: Jeugd voorgeschiedenis pleeggezin, tuchthuis,  
kindertehuis?         NEE 
 
Score is dan 50 procent 
 
Vraag 7: Heeft dit uw handelen beïnvloed?     JA 
 
Hoe heeft dit uw handelen beïnvloed? 
 






Als u dit gedaan heeft schrijft u het weg met <Gereed>. U krijgt dan weer een 
leeg BenRICU scherm. Vervolgens klikt u links boven in de hoek de optie 
<Bestand> aan. En dan <Bestand-naar diskette>. Waarna u de diskette 2 in uw 
diskette station doet en aangeeft welk station dit is voor de computer. Meestal is 
dit a (er hoeft geen dubbele punt achter). De computer schrijft het bestand nu 
weg.  
 
Indien er vragen of problemen zijn kunt u terecht bij Saskia Zandstra (024-
3619235) op maandag, woensdag of donderdag of bij Hans Bor (024-3616645) 






Na 11 jaar “benzo” onderzoek is het tijd om terug te kijken. Een ding staat vast, ook 
al staat alleen mijn naam erop, zonder hulp van velen had dit proefschrift er nooit 
gelegen! Ik moet me helaas beperken tot personen die me veel hebben bijgestaan. 
 
Mijn interesse voor onderzoek is gegroeid tijdens mijn werk bij het ROCARI-
onderzoek in Rotterdam onder directe leiding van Annette Bak en op afstand Rick 
Grobbee. Het geplande onderzoek bij 7000 mannen werd helaas na 2 jaar 
afgebroken door de subsidiegever. Maar van jullie flexibiliteit en vindingrijkheid die 
steeds nodig was om met dit alles om te gaan,  heb ik veel geleerd. Toen ik de 
huisartsopleiding had afgerond en verhuisde naar Nijmegen wist ik een ding zeker. Ik 
wilde graag mijn huisarts werk combineren met onderzoekswerk.  
Zo kwam ik na bijna 2 jaar full-time waarnemen terecht bij het Nijmegen Regio II 
project. Hierbij wil ik de project-commissie,  Ernst Roscam Abbing, Bert Tax,  Paul 
Hodiamont, Frans Zitman en Eloy van de Lisdonk bedanken, voor jullie visie en 
blijvende betrokkenheid om het Nijmegen Regio project I na 20 jaar verbeterd te 
reproduceren. Uiteraard dank ik de patiënten, huisartsen en LINH voor hun 
medewerking en inzet, zodat deze twee onderzoeken mogelijk zijn geworden.  
Een omvangrijk onderzoek brengt met zich mee dat je veel collega’s hebt om de 
dagelijkse problemen mee te delen, Josien van de Berg, Cees Rijnders, Joop Furer, 
Christaine König-Zahn (helaas ben je er niet meer bij), Jan Mulder, Riet Aarts en later 
ook Eric van Rijswijk: zonder jullie was onderzoek doen nooit zo’n leuke bezigheid 
geweest. Bedankt voor jullie stimulerende, steunende en gezellige aanwezigheid. 
Het is er dan toch eindelijk van gekomen. Ook mijn proefschrift ligt hier voor jullie. 
 
Beste Frans, jij was de drijvende kracht binnen het Regio-project achter het “benzo-
onderzoek”. We hebben heftige discussie gehad waar ik veel van heb geleerd. 
Typerend was je vasthoudendheid bij sommige punten. Als het niet meteen lukte 
kwam je er drie besprekingen later wel weer op terug en werd er een weg gevonden. 




Beste Chris, ik leerde je kennen op een nascholing in Malta. Je enorme 
gedrevenheid als het gaat om onderzoek sprak me zeer aan. Zodoende ben ik bij de 
afdeling gaan solliciteren. Je kwam pas later bij dit onderzoek maar je inzet was daar 
niet minder om. Je was een voortreffelijke hulp bij het structureren en comprimeren 
van mijn artikelen. Dank voor je begrip in moeilijke tijden. Je gaf mij de ruimte en het 
vertrouwen om er later weer hard tegenaan te gaan. Voor de WONCA ben je veel 
onderweg, desondanks presteer je het om als eerste te antwoorden op mijn mails. Dit 
moet een hele sport voor je zijn, lijkt me. Als promovendus heb ik hiervan genoten. 
Heel hartelijk dank voor al je wijze lessen.   
 
Beste Eloy, jij was het die me aannam bij het Regio-project, je enthousiasme en 
vrolijkheid werkt aanstekelijk. Als ik tussendoor  even bij je binnenliep met iets waar 
ik mee zat, had je altijd tijd om mee te denken. Zo ging ik dan weer verreikt naar 
buiten, waarvoor dank.  
   
Geen co-promotor,  maar Joop, ik weet niet hoeveel we wel niet hebben gedis-
cussieerd in de afgelopen jaren. Ik kijk op al die momenten met veel genoegen terug. 
Dank je voor al je tijd, inzet en op allerlei vlak je kritische meedenken, dit was en is 
voor mij van onschatbare waarde. 
 
Beste Hans, niet alleen heb je me bij de analyses geholpen en alle medicatie data op 
allerlei manieren geordend. Je was ook de rust zelve als ik om lastige analyses vroeg 
en mijn ideeën hierover vasthield. Behoudens de analyses heb je me ook weer laten 
hardlopen en fietsen. Het was heerlijk en geestverruimend om in de lunchpauze even 
samen lekker hard te rennen, dank je wel. 
 
Mijn dank gaat ook uit naar Henk voor je hulp bij het mee bedenken en controleren 
van de statistisch analyses.  
Om bij de ICT ondersteuning te blijven, waar was ik geweest zonder jou hulp Waling  
met programmatuur voor al die HISsen met hun verschillende aansturingsystemen, 




Beste Nathalie, toen jij bij ons op de kamer kwam was je eerst wat stil tussen al die 
“regio-drukte”. Gelukkig heb ik je in de loop der jaren steeds beter mogen leren 
kennen. Dank je wel voor het delen van ons lief en leed en onze gezellige vakanties 
samen, we gaan zo door. 
 
Beste Mieke, het begon met zomaar een lunchwandelingetje en groeide uit tot 
bijzondere wandelingen en meer. Ik heb ervan genoten en mag er gelukkig nog 
steeds van genieten, dank je wel voor alles. Ik hoop je straks weer terug te zien op 
onze kamer bij de “uni”.  
 
Met kamergenoten deel je toch vaak je eerste frustraties of blijdschap over wat er op 
zo’n dag allemaal gebeurt, bedankt Karin, Lisette, Vivian, Connie en Evelien. 
 
Beste Evelyn, de laatste jaren heb je me wegwijs gemaakt binnen het 
communicatieonderwijs, wat ik erg leuk vind. Je hebt langer moeten wachten dan 
was gepland maar nu is het dan eindelijk klaar. Ik kijk ernaar uit om mijn aandacht 
meer op het onderwijs te richten. 
 
Beste Jan, als mede lid van de blokcommissie Acute Geneeskunde was je 
geïnteresseerd naar mijn vorderingen met “het boekje”. Je was altijd bereid om even 
creatief mee te denken, voor mij een “stoot” nieuwe energie.   
 
Beste Peter, toen jij naar Nijmegen kwam om het GGZ onderzoek verder op te 
bouwen was mochten we genieten van je humor en je rust. Je weet op een plezierige 
manier de vraagstelling helder te krijgen. Met jou, Tim en Lieke was een congres 
bijwonen een zeer aangename en inspirerende bezigheid. Wim, als mede 
“benzo”onderzoeker deelden we soms dezelfde soort problemen en het was altijd 
plezierig om dit samen te bespreken. Hiske  in de korte tijd dat je op de afdeling bent 
heb je al veel meegedacht, dank je wel.   
 
Caroline en Lotte, ik kijk uit naar jullie boekje. Bedankt voor de gezelligheid en steun. 
 
Zonder secretariële ondersteuning is het hard ploeteren Twanny, dank je wel voor je 
hulp bij mijn literatuur database, power point presentaties maar vooral je hulp bij de 
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lay-out van dit proefschrift.  Dorothé, het is altijd fijn om even bij te praten. Caroline 
als bewaakster van Chris zijn agenda vond je altijd wel weer ergens een plekje voor 
mij. Annemarie  in de begin periode van het onderzoek was je er voor de 
uitnodigingsbrieven van het Regio-project. Je bent er altijd met een zelfgemaakte 
verjaardagskaarten of iets lekkers bij de thee, mijn dank. 
 
Natuurlijk ook al de andere collega’s en onderzoekers die nog niet genoemd zijn 
bedankt voor de prettige sfeer, de lunches, de discussies over ons vak, 
refereeravonden of gewoon een gezellig kletspraatje.  
   
Naast dit onderzoekwerk was er al die tijd de praktijk in Uden. De eerste jaren samen 
met mijn collega’s Jur en Coot. Gu die ons praktijkmanagement deed en onze 
assistentes Annie en Kirstin en Yvonne voor de praktijkondersteuning. Sinds 
december 2004 zijn we met z’n allen naar Medipark verhuisd, waar we met 12 
huisartsen en 22 medewerkers werken.  Het is een werk maar ook een genot om zo 
samen te werken en het houdt me met de benen op de grond van ons huisartsenvak. 
Dank je wel voor jullie hulp. 
Beste Coot,  al die jaren was je er, op allerlei manieren. Ik ben blij dat we sinds 2007 
onze praktijk samen delen binnen Medipark. Ik hoop straks nog actiever mee te 
kunnen werken. Gelukkig sta je als paranimf naast me op 20 augustus. 
Beste Frieda, dank je wel voor het kritisch lezen van mijn Nederlandse samenvatting. 
 
Vrienden, familie en buren in Nijmegen, bedankt voor de interesse en de 
broodnodige afleiding. 
 
Pap, mam, bedankt. 
 
Lieve Marjan, ik had me geen betere zus kunnen wensen. We hebben al veel lief en 
leed gedeeld. Je was er toen ik je nodig had. Ik ben erg blij dat je mijn paranimf wilt 
zijn, dank je wel. 
  
Lieve Augusto, jij bent er voor mij voor de zaken buiten dit proefschrift en er is zoveel 





Saskia M. Zandstra werd geboren op 30 november 1963 te Harderwijk. Ze groeide 
achtereenvolgens op in Bunnik, Zeist, Deventer en Gorssel. Ze behaalde het 
atheneum β diploma aan het Revius college te Deventer en ging in 1982 
geneeskunde studeren aan de Rijksuniversiteit te Utrecht. In 1990 behaalde ze haar 
artsexamen. Vervolgens werkte ze als arts-onderzoeker kortdurend voor het 
Doveninstituut in St. Michiels Gestel. Vervolgens heeft ze twee jaar gewerkt als arts-
onderzoeker voor de Stichting ROMERUS gelieerd aan de afdeling epidemiologie 
van de Erasmus Universiteit te Rotterdam. Van 1992 tot en met 1994 volgde ze de 
huisartsopleiding aan de Rijksuniversiteit Leiden. Aan het eind van de opleiding 
verhuisde ze naar Nijmegen. Waarna ze fulltime gewerkt heeft als waarnemer en 
actief was als waarnemer binnen de Regionale Huisartsen Vereniging. Tot ze in 
november 1996 als huisartsonderzoeker begon bij het Regio-project Nijmegen II en 
tegelijkertijd ging samenwerken met Coot Kuipers en Jur Kingma in de 
huisartspraktijk in Uden. In 1997 kwam ook de financiering rond voor het 
deelonderzoek binnen het Regio-project Nijmegen II, te weten: “Signalering van 
langdurig benzodiazepine gebruik in de huisartspraktijk”, waarvan het eindresultaat 
nu voor u ligt. Op de universiteit werkt ze de laatste jaren mee in het onderwijs voor 
het basiscurriculum geneeskunde bij de communicatietraining, de acute 
geneeskunde en psychopathologie.  
In de huisartspraktijk in Uden hebben ze sinds 2002 met 9 huisartspraktijken en de 
apotheek een AHOED opgericht en gebouwd, waar ze naast het huisartsenwerk 
mede verantwoordelijk is voor het medewerkersbeleid als lid van de medewerkers-
commissie van Medipark. Ze is sinds 2007 geassocieerd met Coot Kuipers. 
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 de oplossing voor je angst en/of slapeloosheid
Beter is:
 samen zoeken naar een structurele oplossing
  voor het onderliggende probleem
Benzodiazepinen kunnen  je soms wel even helpen:
 wat meer rust in jezelf te vinden 
 om te zoeken naar je eigen kracht
 zodat je een structurele oplossing
 voor je probleem kunt vinden
Maar pas op!
 Anders heb je er straks een probleem bij
Dus VOORKOM chronisch gebruik van benzodiazepinen,
samen met je (huis)arts
Dat is uiteindelijk in het belang van je genezing
saskiazandstra-prom-feest@live.nl
Voor vragen, email naar:
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